Applied Micro Circuits (AMCC) 10-Q 5 Nov 13 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Sep. 30, 2013	Oct. 31, 2013
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'APPLIED MICRO CIRCUITS CORP	'
Entity Central Index Key	'0000711065	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-13	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'
Current Fiscal Year End Date	'--03-31	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	73,858,343

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Sep. 30, 2013	Mar. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$27,908	$19,065	[1]
Short-term investments-available-for-sale	48,060	66,411	[1]
Accounts receivable, net	26,707	24,575	[1]
Inventories	12,795	12,900	[1]
Other current assets	19,395	17,998	[1]
Total current assets	134,865	140,949	[1]
Property and equipment, net	33,992	34,391	[1]
Goodwill	11,425	13,183	[1]
Purchased intangibles	229	11,991	[1]
Other assets	8,650	10,866	[1]
Total assets	189,161	211,380	[1]
Current liabilities:	'	'
Accounts payable	16,397	17,650	[1]
Accrued payroll and related expenses	5,310	6,158	[1]
Veloce accrued liability	58,251	78,082	[1]
Other accrued liabilities	13,064	10,730	[1]
Deferred revenue	743	1,469	[1]
Total current liabilities	93,765	114,089	[1]
Veloce and other non-current liabilities	1,635	15,787	[1]
Commitments and contingencies (Note 7)	'	'	[1]
Stockholders’ equity:	'	'
Preferred stock, $0.01 par value: Authorized shares - 2,000, none issued and outstanding	0	0	[1]
Common stock, $0.01 par value: Authorized shares - 375,000 at September 30, 2013 and March 31, 2013; Issued and outstanding shares - 73,733 at September 30, 2013 and 67,952 at March 31, 2013	737	680	[1]
Additional paid-in capital	5,965,922	5,926,630	[1]
Accumulated other comprehensive loss	-6,302	-737	[1]
Accumulated deficit	-5,866,596	-5,845,069	[1]
Total stockholders’ equity	93,761	81,504	[1]
Total liabilities and stockholders’ equity	$189,161	$211,380	[1]
[1]	Amounts have been derived from the March 31, 2013 audited consolidated financial statements.

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2013	Mar. 31, 2013
In Thousands, except Per Share data, unless otherwise specified
Statement of Financial Position [Abstract]	'	'
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	2,000	2,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	375,000	375,000
Common stock, shares issued	73,733	67,952
Common stock, shares outstanding	73,733	67,952

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Net revenues	$55,387	$46,324	$109,535	$87,618
Cost of revenues	21,397	20,561	43,739	38,916
Gross profit	33,990	25,763	65,796	48,702
Operating expenses:	'	'	'	'
Research and development	56,550	34,383	91,056	69,154
Selling, general and administrative	9,146	13,531	18,672	26,001
Gain on sale of TPack	0	0	-19,699	0
Amortization of purchased intangible assets	62	601	192	1,251
Restructuring charges, net	999	0	1,092	0
Total operating expenses	66,757	48,515	91,313	96,406
Operating loss	-32,767	-22,752	-25,517	-47,704
Interest income (expense), net	488	745	4,154	2,424
Other income (expense), net	88	90	217	173
Loss before income taxes	-32,191	-21,917	-21,146	-45,107
Income tax expense (benefit)	192	-360	380	-160
Net loss	($32,383)	($21,557)	($21,526)	($44,947)
Basic and diluted net loss per share (in dollars per share)	($0.45)	($0.33)	($0.30)	($0.71)
Weighted Average Number of Shares Outstanding, Basic and Diluted	72,610	64,947	70,985	63,678

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Net loss	($32,383)	($21,557)	($21,526)	($44,947)
Other comprehensive loss, net of tax:	'	'	'	'
Unrealized gain (loss) on investments	-696	1,358	-5,225	855
Loss on foreign currency translation	-151	-6	-340	-122
Other comprehensive gain (loss), net of tax:	-847	1,352	-5,565	733
Total comprehensive loss	-33,230	-20,205	-27,091	-44,214
Reclassification adjustment from AOCI to earnings, short term investments	$86	$177	$3,284	$1,194

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013		Sep. 30, 2012
Operating activities:	'		'
Net loss	($21,526)		($44,947)
Adjustments to reconcile net loss to net cash used for operating activities:	'		'
Depreciation	5,283		4,905
Amortization of purchased intangibles	358		2,609
Stock-based compensation expense:	'		'
Stock options	1,336		2,172
Restricted stock units	6,212		13,151
Warrants	0		1,289
Veloce accrued liability	39,739		4,650
Acquisition related adjustment	0		-133
Gain on sale of TPack	-19,699		0
Net loss on disposals of property, equipment and other assets	27		3
Non-cash restructuring costs	298		0
Tax effect on other comprehensive income	0		-565
Changes in operating assets and liabilities:	'		'
Accounts receivable	-2,366		8,391
Inventories	105		4,807
Other assets	-159		-2,735
Accounts payable	-1,943		-4,293
Accrued payroll and other accrued liabilities	1,810		-1,819
Veloce accrued liability	-44,240		-14,814
Deferred revenue	-594		-918
Net cash used for operating activities	-35,359		-28,247
Investing activities:	'		'
Proceeds from sales and maturities of short-term investments	21,303		24,868
Purchases of short-term investments	-8,177		-15,361
Proceeds from sale of property, equipment and other assets	20		0
Purchase of property, equipment and other assets	-2,023		-7,606
Proceeds from sale of strategic equity investment	1,286		7,146
Purchases of strategic equity investment	0		-500
Proceeds from the sale of TPack, net	-29,498		0
Net cash provided by investing activities	41,907		8,547
Financing activities:	'		'
Proceeds from issuance of common stock	4,439		5,359
Proceeds from employee stock purchase plan	2,497		0
Funding of restricted stock units withheld for taxes	-4,079		-313
Repurchase of common stock	0		-654
Payment of contingent consideration	0		-485
Other	-562		-280
Net cash provided by financing activities	2,295		3,627
Net increase (decrease) in cash and cash equivalents	8,843		-16,073
Cash and cash equivalents at beginning of year	19,065	[1]	28,065
Cash and cash equivalents at end of period	27,908		11,992
Supplementary cash flow disclosures:	'		'
Income taxes	379		197
Common stock issued for Veloce merger consideration	$29,041		$14,842
[1]	Amounts have been derived from the March 31, 2013 audited consolidated financial statements.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	6 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'
	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Basis of Presentation
	The Condensed Consolidated Financial Statements include all the accounts of AppliedMicro (the "Company") and its wholly-owned subsidiaries including Veloce Technologies Inc. (“Veloce”), which was consolidated in prior accounting periods prior to its merger with the Company, as a variable interest entity (“VIE”) since the Company was determined to be its primary beneficiary. On June 20, 2012, the Company completed the acquisition of Veloce which became a wholly owned subsidiary of the Company as of this date. See Note 4, Veloce, to the Condensed Consolidated Financial Statements. All significant intercompany balances and transactions have been eliminated in consolidation.
	Use of Estimates
	The preparation of financial statements in accordance with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of net revenue and expenses in the reporting period. The Company regularly evaluates estimates and assumptions related to its:
	•	capitalized mask sets including its useful lives, which affects cost of goods sold and property and equipment or Research and Development ("R&D") expenses, if not capitalized;
	•	inventory valuation, warranty liabilities and revenue reserves, which affects cost of sales, gross margin, and revenues;
	•	allowance for doubtful accounts, which affects operating expenses;
	•	unrealized losses or other-than-temporary impairments of short-term investments available for sale, which affects interest income (expense), net;
	•	valuation of purchased intangibles and goodwill, which affects amortization and impairments of purchased intangibles, impairments of goodwill and apportionment of goodwill related to divestitures;
	•	Veloce accrued liability which considers: (i) estimating the total value of the expected Veloce consideration, (ii) determining the stage at which a milestone is deemed to be probable of attainment, (iii) the estimated progress towards achieving the milestone at the time such milestone was deemed probable of achievement and (iv) estimating the approximate timing of the expected completion of the milestones and related payments;
	•	potential costs of litigation, which affects operating expenses;
	•	valuation of deferred income taxes, which affects income tax expense (benefit); and
	•	stock-based compensation, which affects gross margin and operating expenses.
	The Company bases its estimates and assumptions on historical experience and on various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from management’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.
	Recently Adopted Accounting Pronouncements
	In February 2013, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update 2013-02 (ASU 2013-02), Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income. ASU 2013-02 requires an entity to present either on the face of the statement where comprehensive income is presented or in the notes to the financial statements, significant amounts reclassified out of accumulated other comprehensive income by the respective line items of net income. The adoption of ASU 2013-02, which involves presentation and disclosures only, did not have a significant impact on the Company's Condensed Consolidated Financial Statements.
	In July 2013, the FASB issued Accounting Standards Update 2013-11 amending Income Taxes: Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists that will require the presentation of certain unrecognized tax benefits as reductions to deferred tax assets rather than as liabilities in the condensed consolidated balance sheets when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. The amendments will be effective for interim and annual periods beginning after December 15, 2013; however, early adoption and retrospective application are permitted. The Company does not expect the adoption of these amendments to have a significant impact on the Company’s Condensed Consolidated Financial Statements.

Certain_Financial_Statement_In

Certain Financial Statement Information	6 Months Ended
	Sep. 30, 2013
Certain Financial Statement Information [Abstract]	'
CERTAIN FINANCIAL STATEMENT INFORMATION	'
	CERTAIN FINANCIAL STATEMENT INFORMATION
	Accounts receivable:
			September 30,				March 31,
			2013				2013
			(In thousands)
	Accounts receivable		$	27,165			$	25,278
	Less: allowance for bad debts		(458		)		(703		)
			$	26,707			$	24,575
	Inventories:
			September 30,				March 31,
			2013				2013
			(In thousands)
	Finished goods		$	5,802			$	7,247
	Work in process		4,778				4,098
	Raw materials		2,215				1,555
			$	12,795			$	12,900
	Other current assets:
			September 30,				March 31,
			2013				2013
			(In thousands)
	Prepaid expenses		$	12,321			$	13,762
	Executive deferred compensation assets		1,075				693
	Deposits		652				828
	Receivable from sale of strategic investment and TPack		3,353				1,331
	Other		1,994				1,384
			$	19,395			$	17,998
	Property and equipment:
			Useful		September 30,				March 31,
			Life		2013				2013
			(In years)		(In thousands)
	Machinery and equipment *		7-May		$	44,900			$	40,063
	Leasehold improvements		15-Jan		11,480				14,202
	Computers, office furniture and equipment		7-Mar		43,845				43,485
	Buildings		31.5		2,756				2,756
	Land		—		9,800				9,800
					112,781				110,306
	Less: accumulated depreciation and amortization				(78,789		)		(75,915		)
					$	33,992			$	34,391
	* Includes capitalized mask costs.
	Goodwill and purchased intangibles:
	Goodwill is as follows:
		September 30,				March 31,
		2013				2013
		(In thousands)
	Goodwill	$	11,425			$	13,183
	The reduction in Goodwill of $1.8 million relates to the sale of TPack. Please refer to Note 8, Sale of TPack A/S, to the Condensed Consolidated Financial Statements for details.
	Purchase-related intangibles were as follows:
			30-Sep-13															31-Mar-13
			Gross				Accumulated				Net				Weighted			Gross			Accumulated				Net			Weighted
							Amortization								average						Amortization							average
							and Impairments								remaining						and Impairments							remaining
															useful life													useful life
			(In thousands)												(In years)			(In thousands)										(In years)
	Developed technology/in-process research and development		$	425,000			$	(425,000	)		$	—			—			$	441,300		$	(431,771	)		$	9,529		3.5
	Customer relationships		6,330				(6,101		)		229				0.9			12,830			(10,507		)		2,323			2.1
	Patents/core technology rights/tradename		62,306				(62,306		)		—				—			63,206			(63,067		)		139			0.3
			$	493,636			$	(493,407	)		$	229						$	517,336		$	(505,345	)		$	11,991
	During the quarter ended June 30, 2013, $11.4 million of purchased intangibles were written off pursuant to the sale of TPack. Please refer to Note 8, Sale of TPack A/S, to the Condensed Consolidated Financial Statements for further discussion.
	As of September 30, 2013, the estimated future amortization expense of purchased intangible assets to be charged to operating expenses was as follows (in thousands):
			Operating
			Expenses
	Fiscal Years Ending March 31,
	2014 (remainder of year)		$	125
2015		104
2016 and thereafter		—
Total		$	229
Other assets:
		September 30,				March 31,
		2013				2013
		(In thousands)
Non-current portion of prepaid expenses		$	5,650			$	7,866
Strategic investments		3,000				3,000
		$	8,650			$	10,866
Other accrued liabilities:
		September 30,				March 31,
		2013				2013
		(In thousands)
Employee related liabilities		$	2,168			$	2,236
Executive deferred compensation		1,310				1,284
Income taxes		1,127				903
Professional fees		3,977				3,840
Other		4,482				2,467
		$	13,064			$	10,730
Strategic Investments
The Company has entered into certain equity investments in privately held businesses to achieve certain strategic business objectives. The Company’s investments in equity securities of privately held businesses are accounted for under the cost method. Under the cost method, strategic investments in which the Company holds less than a 20% voting interest and in which the Company does not have the ability to exercise significant influence are carried at cost reduced by other-than-temporary impairments, as appropriate. These investments are included in other assets on the Company’s Condensed Consolidated Balance Sheets. The Company periodically reviews these investments for other-than-temporary declines in fair value based on the specific identification method and writes down investments when an other-than-temporary decline has occurred. During the six months ended September 30, 2013 and 2012, the Company did not record any other-than-temporary impairment charges of its strategic investments and invested zero and $0.5 million, respectively, in non-marketable equity investments and these amounts are carried at cost.
Short-term investments:
The following is a summary of cash, cash equivalents and available-for-sale investments by type of instrument (in thousands):
		30-Sep-13																31-Mar-13
		Amortized				Gross Unrealized								Estimated				Amortized			Gross Unrealized							Estimated
		Cost				Gains				Losses				Fair Value				Cost			Gains				Losses			Fair Value
Cash		$	20,652			$	—			$	—			$	20,652			$	8,529		$	—			$	—		$	8,529
Cash equivalents		7,256				—				—				7,256				10,536			—				—			10,536
U.S. Treasury securities and agency bonds		12,400				12				2				12,410				12,363			10				—			12,373
Corporate bonds		11,927				45				1				11,971				15,567			63				2			15,628
Mortgage-backed and asset-backed securities*		4,144				339				25				4,458				3,655			355				7			4,003
Closed-end bond funds		14,374				2,120				530				15,964				21,914			5,340				39			27,215
Preferred stock		2,406				851				—				3,257				4,878			2,314				—			7,192
		$	73,159			$	3,367			$	558			$	75,968			$	77,442		$	8,082			$	48		$	85,476
Reported as:
Cash and cash equivalents														$	27,908													$	19,065
Short-term investments available-for-sale														48,060														66,411
														$	75,968													$	85,476
* At September 30, 2013 and March 31, 2013, approximately $1.2 million and $1.4 million of the estimated fair value presented were mortgage-backed securities, respectively.
The established guidelines for measuring fair value and expanded disclosures regarding fair value measurements are defined as a three-level valuation hierarchy for disclosure of fair value measurements as follows:
Level 1 — Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.
Level 2 — Inputs (other than quoted market prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life.
Level 3 — Inputs reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. Valuation of instruments includes unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of assets or liabilities.
The following is a summary of cash, cash equivalents and available-for-sale investments by type of instrument measured at fair value on a recurring basis (in thousands):
		30-Sep-13																31-Mar-13
		Level 1				Level 2				Level 3				Total				Level 1			Level 2				Level 3			Total
Cash		$	20,652			$	—			$	—			$	20,652			$	8,529		$	—			$	—		$	8,529
Cash equivalents		7,156				100				—				7,256				9,508			1,028				—			10,536
U.S. Treasury securities and agency bonds		11,951				459				—				12,410				12,373			—				—			12,373
Corporate bonds		—				11,971				—				11,971				—			15,628				—			15,628
Mortgage-backed and asset-backed securities		—				4,458				—				4,458				—			4,003				—			4,003
Closed-end bond funds		15,964				—				—				15,964				27,215			—				—			27,215
Preferred stock		—				3,257				—				3,257				—			7,192				—			7,192
		$	55,723			$	20,245			$	—			$	75,968			$	57,625		$	27,851			$	—		$	85,476
There were no significant transfers in and out of Level 1 and Level 2 fair value measurement categories during the three and six months ended September 30, 2013 and 2012.
The following is a summary of the cost and estimated fair values of available-for-sale securities with stated maturities, which include U.S. Treasury securities and agency bonds, corporate bonds and mortgage-backed and asset-backed securities, by contractual maturity (in thousands):
		30-Sep-13								31-Mar-13
		Cost				Fair Value				Cost				Fair Value
Less than 1 year		$	7,867			$	8,040			$	9,205			$	9,217
Mature in 1 – 2 years		19,341				19,386				19,843				20,040
Mature in 3 – 5 years		353				446				1,575				1,649
Mature after 5 years		910				967				962				1,098
		$	28,471			$	28,839			$	31,585			$	32,004
The following is a summary of gross unrealized losses as of (in thousands):
		Less Than 12 Months of								12 Months or More of								Total
		Unrealized Losses								Unrealized Losses
As of September 30, 2013		Estimated				Gross				Estimated				Gross				Estimated			Gross
		Fair				Unrealized				Fair				Unrealized				Fair			Unrealized
		Value				Losses				Value				Losses				Value			Losses
U.S. Treasury securities and agency bonds		$	1,468			$	(2	)		$	—			$	—			$	1,468		$	(2	)
Corporate bonds		1,654				(1		)		—				—				1,654			(1		)
Mortgage-backed and asset-backed securities		1,675				(25		)		12				—				1,687			(25		)
Closed-end bond funds		4,705				(448		)		391				(82		)		5,096			(530		)
		$	9,502			$	(476	)		$	403			$	(82	)		$	9,905		$	(558	)
		Less Than 12 Months of								12 Months or More of								Total
		Unrealized Losses								Unrealized Losses
As of March 31, 2013		Estimated				Gross				Estimated				Gross				Estimated			Gross
		Fair				Unrealized				Fair				Unrealized				Fair			Unrealized
		Value				Losses				Value				Losses				Value			Losses
U.S. Treasury securities and agency bonds		$	300			$	—			$	—			$	—			$	300		$	—
Corporate bonds		2,276				(2		)		113				—				2,389			(2		)
Mortgage-backed and asset-backed securities		647				(3		)		—				(4		)		647			(7		)
Closed-end bond funds		—				—				6,991				(39		)		6,991			(39		)
		$	3,223			$	(5	)		$	7,104			$	(43	)		$	10,327		$	(48	)
Other-Than-Temporary Impairment
Based on an evaluation of securities that have been in a loss position, the Company did not recognize any other-than-temporary impairment charges for the three and six months ended September 30, 2013 and 2012. The Company considered various factors which included a credit and liquidity assessment of the underlying securities and the Company’s intent and ability to hold the underlying securities until the estimated date of recovery of its amortized cost. As of September 30, 2013 and March 31, 2013, the Company also had $3.4 million and $8.1 million in gross unrealized gains, respectively. The basis for computing realized gains or losses is by specific identification.
Warranty reserves:
The Company's products typically carry a one year warranty. The Company establishes reserves for estimated product warranty costs at the time revenue is recognized. Although the Company engages in extensive product quality programs and processes, its warranty obligation is affected by product failure rates, use of materials and service delivery costs incurred in correcting any product failure. Should actual product failure rates, use of materials or service delivery costs differ from the Company's estimates, additional warranty reserves could be required which could reduce its gross margin.
The following table summarizes warranty reserve activity (in thousands):
	Three Months Ended								Six months ended
	September 30,								September 30,
	2013				2012				2013				2012
Beginning balance	$	203			$	447			$	220			$	454
Charged to costs of revenues	(11		)		85				(26		)		215
Cost incurred	(5		)		(162		)		(7		)		(299		)
Ending balance	$	187			$	370			$	187			$	370
Interest income (expense), net (in thousands):
		Three Months Ended								Six months ended
		September 30,								September 30,
		2013				2012				2013				2012
Interest income		$	402			$	568			$	870			$	1,230
Net realized gain on short-term investments		86				177				3,284				1,194
		$	488			$	745			$	4,154			$	2,424
Net loss per share:
Shares used in basic net loss per share are computed using the weighted average number of common shares outstanding during each period. Shares used in diluted net loss per share include the dilutive effect of common shares potentially issuable upon the exercise of stock options, vesting of RSUs and outstanding warrants. The reconciliation of shares used to calculate basic and diluted net loss per share consists of the following (in thousands, except per share data):
		Three Months Ended								Six months ended
		September 30,								September 30,
		2013				2012				2013				2012
Net loss		$	(32,383	)		$	(21,557	)		$	(21,526	)		$	(44,947	)
Shares used in net loss per share computation:
Weighted average common shares outstanding, basic		72,610				64,947				70,985				63,678
Net effect of dilutive common share equivalents		—				—				—				—
Weighted average common shares outstanding, diluted		72,610				64,947				70,985				63,678
Basic and diluted net loss per share		$	(0.45	)		$	(0.33	)		$	(0.30	)		$	(0.71	)
The effect of anti-dilutive securities (comprised of options and restricted stock units) totaling 4.3 million and 5.2 million equivalent shares for the three and six months ended September 30, 2013, respectively, and 10.2 million and 10.3 million equivalent shares for the three and six months ended September 30, 2012, respectively, have been excluded from the net loss per share computation, as their impact would be anti-dilutive.
The effect of dilutive securities (comprised of options and restricted stock units) totaling 1.7 million and 1.3 million shares for the three and six months ended September 30, 2013, respectively, and 0.5 million and 0.4 million shares for the three and six months ended September 30, 2012, respectively, have been excluded from the net loss per share computation, as their impact would be anti-dilutive because the Company incurred net losses in the periods presented.
Total equivalent shares excluded from the net loss per share computation are 6.0 million and 6.5 million for the three and six months ended September 30, 2013, respectively, and 10.7 million each for the three and six months ended September 30, 2012.

Restructuring_Charges

Restructuring Charges	6 Months Ended
	Sep. 30, 2013
Restructuring and Related Activities [Abstract]	'
RESTRUCTURING CHARGES	'
	RESTRUCTURING CHARGES
	The Company recognizes restructuring costs related to asset impairment and exit or disposal activities. Costs relating to facilities closure or lease commitments are recognized when the facility has been exited. Termination costs are recognized when the costs are deemed both probable and estimable.
	December 2012 Restructuring Program
	In December 2012, the Company implemented a restructuring program to reorganize its operations and reduced its workforce by approximately 70 employees. The plan included eliminating job redundancies, reducing the Company's workforce and impairing the unamortized value of a software intellectual property license, which the Company no longer intends to use to develop new products. The Company anticipates that the restructuring plan will reduce ongoing headcount expenses by approximately $8.0 million to $9.0 million annually and other additional operational expenses by $4.0 million to $5.0 million annually which is in line with the Company's original estimate. Total costs incurred and expected to be incurred as of September 30, 2013 in connection with the restructuring plan are $1.8 million.
	August 2013 Restructuring Program
	In August 2013, the Company implemented a restructuring program to reorganize its operations and reduced its workforce by approximately 20 employees. The plan included eliminating job redundancies, reducing the Company's workforce and impairing the unamortized value of a software intellectual property license, which the Company no longer intends to use to develop new products. The Company anticipates that the restructuring plan will reduce ongoing headcount expenses by approximately $3.0 million annually and other additional operational expenses by $0.5 million annually. The Company currently estimates that, as part of this restructuring action, it will recognize total restructuring charges of approximately $1.0 million consisting of severance and other one-time termination benefits and impairment of an asset.
	The restructuring activity during the six months ended September 30, 2013 relating to the December 2012 and August 2013 restructuring programs is as follows (in thousands):
		Workforce Reduction			Asset Impairment			Total
	Liability, March 31, 2013	$	548		$	—		$	548
	Restructuring charges	93			—			$	93
	Cash payments	(334		)	—			$	(334	)
	Liability, June 30, 2013	307			—			307
	Restructuring charges	727			272			999
	Non-cash items	—			(272		)	(272		)
	Cash payments	(847		)	—			(847		)
	Liability, September 30, 2013	$	187		$	—		$	187

Veloce

Veloce	3 Months Ended
	Sep. 30, 2013
Variable Interest Entity, Measure of Activity [Abstract]	'
VELOCE	'
	VELOCE
	On June 20, 2012 (the “Closing Date”), the Company completed its acquisition of Veloce pursuant to the terms of the Agreement and Plan of Merger (the “Merger Agreement”). Veloce has been developing specific technology for the Company.
	The terms of the Merger Agreement include the payment of the total consideration, payable to holders of Veloce common stock options that were vested on the Closing Date and holders of Veloce common stock and stock equivalents (collectively “Veloce Equity Holders”), and to Veloce stock equivalents that have not yet been allocated to individuals (“Unallocated Veloce Units”). The Merger Agreement further provides for payments of additional merger consideration contingent upon the achievement of certain post-closing product development milestones relating to the Veloce development project.
	The total estimated consideration to be paid is based upon the benchmarks achieved during simulations that were performed during the third quarter of fiscal 2013 and correlation of the results of the simulations to the contractual terms included in the Merger Agreement. As a result of higher than expected benchmarks achieved during simulations, the total estimated consideration to be paid was updated during fiscal 2013 from a previous estimated maximum of approximately $135.0 million to the contractual maximum of $178.5 million. Significant judgment is required in assessing when a performance milestone is probable of achievement and estimating the percentage of completion of the milestone and the timing of when the performance milestones will be completed. These determinations are based on discussions with internal technical personnel that address various qualitative and quantitative factors, including, but not limited to, overall complexity associated with the assessment, stage of development, progress made to date, results of testing and consideration as to the nature of the remaining development work.
	The Company has completed the first and second performance milestones and assessed the third and final performance milestone relating to the Veloce project as probable of achievement as of September 30, 2013. The consideration relating to the first, second and third and final performance milestones, excluding the value allocated to the Unallocated Veloce Units and the remaining portion of the third and final milestone, in the amount of $166.3 million, has been recognized as research and development expense through September 30, 2013 compared to $65.1 million as of September 30, 2012. During the three and six months ended September 30, 2013, as part of the above arrangement, the Company paid approximately $19.2 million and $44.2 million, respectively, in cash and issued approximately 2.3 million shares and 3.7 million shares, respectively, valued at approximately $19.0 million and $29.0 million, respectively. During the three and six months ended September 30, 2012, as part of the above arrangement, the Company paid approximately $2.1 million and $14.8 million, respectively, in cash and issued approximately 0.2 million shares and 2.6 million shares, respectively, valued at approximately $1.1 million and $14.8 million, respectively.
	The consideration that the Company will be obligated to pay will be allocated equally to each of the Veloce Equity Holders and the Unallocated Veloce Units. The Company is contractually required to distribute all Unallocated Veloce Units within a certain time period. During the three and six months ended September 30, 2013, the Company distributed an additional 12,000 and 0.5 million Unallocated Veloce units which had a related expense of $0.2 million and $5.9 million, respectively. Veloce Equity Holders subject to vesting requirements will receive their distribution upon satisfaction of such vesting requirements.
	For accounting purposes, the costs incurred in connection with the development milestones relating to Veloce is considered compensatory and is recognized as R&D expense. Recognition of these costs as expense will generally occur when certain development and performance milestones become probable of achievement and are deemed earned. However, the value allocated to the Unallocated Veloce Units will not be recognized as R&D expense until distribution of the underlying units occurs. As of September 30, 2013, 0.8 million Unallocated Veloce Units had not been allocated, and the maximum potential additional expense to be recognized associated with these Unallocated Veloce Units is approximately $9.4 million.
	Total R&D expenses recognized were approximately $30.4 million and $39.7 million during the three and six months ended September 30, 2013, respectively, and approximately $2.3 million and $4.6 million during the three and six months ended September 30, 2012, respectively. The Veloce accrued liability included on the Condensed Consolidated Balance Sheets is based upon the amount of R&D expense recognized in connection with the development of the Veloce performance milestones less amounts paid either in cash or our common stock. Veloce consideration that has been accrued as of September 30, 2013 is classified as long-term if payments of the consideration are expected to occur beyond a 12 month period.

Stockholders_Equity

Stockholders' Equity	6 Months Ended
	Sep. 30, 2013
Stockholders' Equity Note [Abstract]	'
STOCKHOLDERS' EQUITY	'
	STOCKHOLDERS’ EQUITY
	Preferred Stock
	The Certificate of Incorporation allows for the issuance of up to two million shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof, including dividend rights, dividend rates, conversion rights, voting rights, terms of redemption, redemption prices, liquidation preferences, and the number of shares constituting any series of the designation of such series, without further vote or action by the stockholders. At September 30, 2013, there are no preferred shares outstanding.
	Common Stock
	At September 30, 2013, the Company had 375.0 million shares authorized for issuance and approximately 73.7 million shares issued and outstanding. At March 31, 2013, there were approximately 68.0 million shares issued and outstanding.
	Employee Stock Purchase Plan ("ESPP")
	The Company had in effect the 1998 Employee Stock Purchase Plan ("1998 Plan") under which 4.8 million shares of common stock were reserved for issuance. In August 2010, the Company’s stockholders approved the proposal to increase the number of shares reserved for issuance to 6.3 million shares. In August 2012, the Company’s stockholders approved the proposal to reserve an additional 1.8 million shares under the 2012 Employee Stock Purchase Plan ("2012 Plan"). Upon adoption of the 2012 Plan, the 1998 Plan was terminated. Under the terms of the 2012 Plan, purchases are made semiannually and the purchase price of the common stock is equal to 85% of the fair market value of the common stock on the first or last day of the offering period, whichever is lower. During the six months ended September 30, 2013 and 2012, 0.3 million and zero shares were issued under the 2012 plan, respectively. In addition, during the six months ended September 30, 2012, 0.4 million shares were issued under the 1998 plan. At September 30, 2013, 0.8 million shares were available for future issuance from the 2012 Plan.
	Stock Repurchase Program
	In August 2004, the Board of Directors authorized a stock repurchase program for the repurchase of up to $200.0 million of the Company's common stock. Under the program, the Company is authorized to make purchases in the open market or enter into structured agreements. In October 2008, the Board of Directors increased the stock repurchase program by $100.0 million. There were no stock repurchases during the six months ended September 30, 2013. During the six months ended September 30, 2012, approximately 0.1 million shares were repurchased on the open market at a weighted average price of $5.18 per share. From the time the program was first implemented in August 2004, the Company has repurchased on the open market a total of 17.3 million shares at a weighted average price of $10.04 per share. All repurchased shares were retired upon delivery to the Company. As of September 30, 2013, the Company had $15.9 million available in its stock repurchase program.
	Stock Options
	The Company has granted stock options to employees and non-employee directors under several plans. These option plans include two stockholder-approved plans (the 1992 Stock Option Plan and 1997 Directors’ Stock Option Plan) and four plans not approved by stockholders (the 2000 Equity Incentive Plan, Cimaron Communications Corporation’s 1998 Stock Incentive Plan assumed in the fiscal 1999 merger, and JNI Corporation’s 1997 and 1999 Stock Option Plans assumed in the fiscal 2004 merger). Certain other outstanding options were assumed through the Company’s various acquisitions.
	In April 2011, the Compensation Committee and the Board of Directors approved the Company’s 2011 Equity Incentive Plan (“2011 Plan”). The Company’s stockholders approved the 2011 Plan during its August 2011 annual meeting. The 2011 Plan serves as a successor to the 1992 Plan and no additional equity awards will be granted under the 1992 Plan. The total number of shares of common stock reserved for issuance under the 2011 Plan consists of 4.2 million shares plus up to 10.9 million shares subject to any stock awards under the 1992 Plan or the 2000 Plan that terminate or are forfeited or repurchased and would otherwise be returned to the share reserve under the 1992 Plan or the 2000 Plan, respectively.
	The Board has delegated administration of the Company’s equity plans to the Compensation Committee, which generally determines eligibility, vesting schedules and other terms for awards granted under the plans. Options under the plans expire not more than ten years from the date of grant and are generally exercisable upon vesting. Vesting generally occurs over four years. New hire grants generally vest and become exercisable at the rate of 25% on the first anniversary of the date of grant and ratably on a monthly basis over a period of 36 months thereafter; subsequent option grants to existing employees generally vest and become exercisable ratably on a monthly basis over a period of 48 months measured from the date of grant.
	During the six months ended September 30, 2013 and 2012, there were no shares of common stock subject to repurchase. Options are granted at prices at least equal to fair value of the Company’s common stock on the date of grant.
	Option activity under the Company’s stock incentive plans during the six months ended September 30, 2013 is set forth below (in thousands, except per share data):
			Number of Shares		Weighted Average
					Exercise Price
					Per Share
	Outstanding at the beginning of the year		3,492		$	10.26
	Granted		40		7.35
	Exercised		(495	)	8.97
	Cancelled		(367	)	10.15
	Outstanding at the end of the period		2,670		$	10.47
	Vested and expected to vest at the end of the period		2,667		$	10.47
	Vested and exercisable at the end of the period		2,512		$	10.56
	At September 30, 2013, the weighted average remaining contractual term for options outstanding and vested is 2.9 years.
	The aggregate pretax intrinsic value of options exercised during the six months ended September 30, 2013 was approximately $1.3 million. This intrinsic value represents the excess of the fair market value of the Company’s common stock on the date of exercise over the exercise price of such options.
	The weighted average remaining contractual life and weighted average per share exercise price of options outstanding and of options exercisable as of September 30, 2013 were as follows (in thousands, except exercise prices and years):
			Options Outstanding						Options Exercisable
	Range of Exercise Prices		Number of		Weighted		Weighted		Number of	Weighted
			Shares		Average		Average		Shares	Average
					Remaining		Exercise Price			Exercise Price
					Contractual
					Life
	$  1.68 - $ 7.60		570		3.54		$	6.69	472	$	6.58
	7.61 - 7.67		650		2.84		7.67		650	7.67
	7.68 - 11.86		469		3.6		10.45		431	10.34
	11.87 - 14.20		599		2.63		12.78		577	12.81
	14.21 - 23.32		382		1.61		17.26		382	17.26
	$  1.68 - $23.32		2,670		2.9		$	10.47	2,512	$	10.56
	As of September 30, 2013, the aggregate pre-tax intrinsic value of options outstanding and exercisable was approximately $8.3 million and $7.7 million, respectively. The aggregate pre-tax intrinsic values were calculated based on the closing price of the Company’s common stock of $12.90 on September 30, 2013.
	Restricted Stock Units ("RSUs")
	The Company has granted RSUs pursuant to its 1992 Plan, 2000 Equity Incentive Plan and 2011 Equity Incentive Plan as part of its regular annual employee equity compensation review program as well as to new hires. RSUs are share awards that, upon vesting, will deliver to the holder, shares of the Company’s common stock. Generally, RSUs vest ratably on a quarterly basis over four years from the date of grant. For employees hired after May 15, 2006, RSUs will vest on a quarterly basis over four years from the date of hire provided that no shares will vest during the first year of employment, at the end of which the shares that would have vested during that year will vest and the remaining shares will vest over the remaining 12 quarters.
	In May 2009, the Company issued three-year performance-based RSU grants, or “EBITDA” Grants, which were completed in fiscal 2012, and no additional grants will be made under this grant.
	In April 2011, the Committee authorized additional three-year performance-based RSU grants, or “EBITDA2” Grants. EBITDA2 Grants are similar to the EBITDA Grant program introduced in 2009. Fiscal 2012 and 2013 were declared as zero attainment years and vesting target shares have rolled over to fiscal 2014. The Company expects that all shares issued under the EBITDA2 program will expire unvested when the program concludes in May 2014.
	In November 2011 and February 2012, the Committee authorized additional 18-month performance-based RSU grants, or “Performance Retention" Grants, which are intended to incentivize superior performance and retain key employees. In May 2012, the Committee authorized 12-month Performance Retention Grants. Vesting for the Performance Retention Grants is subject to (i) the accomplishment of goals and objectives of the individual’s business unit and (ii) individual performance as measured by the accomplishment of individual goals and objectives. The 18-month RSU shares generally vested 2/3 after one year, with certain unearned amounts able to roll over to the subsequent vesting period, and 1/3 after 18 months. The 12-month RSU shares had the opportunity to vest after 1 year. Unvested RSU shares remaining at the end of the program period expired unvested. This program has concluded and no further grants will be made under this program.
	In February 2012, Dr. Gopi was awarded 500,000 performance-based restricted stock units based on three underlying performance milestones. The value of these restricted stock units is $3.7 million. The award associated with each underlying milestone will vest only if the Company's performance milestones relating to the Veloce merger are satisfied; otherwise they will expire unvested. The Company evaluates the probability of achieving the milestones and recognizes expense accordingly. As of September 30, 2013, two of the performance milestones have been completed and the third and final performance milestone was assessed as being probable of attainment, and the associated stock-based compensation expense has been recorded in the Company's Condensed Consolidated Financial Statements.
	In May 2013, the Committee authorized performance-based market stock units or "MSUs". The MSUs will be earned, if at all, based on the Company's Total Shareholder Return (“TSR”) compared to that of the SPDR S&P Semiconductor Index ("Index”) over a two-year performance period (for half of the MSU award) and a three-year performance period (for the remaining half of the MSU award). The MSUs will vest between ranges of 0% and 150% based on the Company's relative TSR compared to the Index. The MSUs were valued using the Monte Carlo pricing model, which uses the Company's stock price, the Index value, expected volatilities of the Company's stock price and the Index, correlation coefficients and risk free interest rates to determine the fair value.
	In May 2013, the Committee authorized an annual incentive compensation plan the (“FY2014 Short Term Plan”), that, if earned, would become payable on May 15, 2014. The FY 2014 Short Term Plan will pay out based on FY 2014 revenue and non-GAAP earnings per share metrics. The award payouts for each corporate financial measure will range from 50% to 150% of the pre-established target level based on the Company's actual performance for fiscal 2014.
	Restricted stock unit activity during the six months ended September 30, 2013 is set forth below (in thousands):
		Number of Shares
	Outstanding at the beginning of the year	6,444
	Awarded	2,032
	Vested	(1,649	)
	Cancelled	(1,452	)
	Outstanding at the end of the period	5,375
	The weighted average remaining contractual term for the restricted stock units outstanding as of September 30, 2013 was 1.1 years.
	As of September 30, 2013, the aggregate pre-tax intrinsic value of restricted stock units outstanding was $69.3 million which includes performance-based awards which are subject to milestone attainment. The aggregate pretax intrinsic values were calculated based on the closing price of the Company’s common stock of $12.90 on September 30, 2013.
	The aggregate pretax intrinsic value of RSUs released during the six months ended September 30, 2013 was $14.4 million. This intrinsic value represents the fair market value of the Company’s common stock on the date of release.
	Warrants
	On May 17, 2009, the Company entered into a development agreement with Veloce pursuant to which Veloce agreed, among other things, to perform development work for the Company on an exclusive basis for up to five years for cash and other consideration, including a warrant to purchase shares of the Company’s common stock (the “Warrant”). In connection with the Merger Agreement amendment entered into on April 5, 2012, the Company and Veloce further modified the Warrant by fully accelerating the vesting schedule resulting in the recognition of approximately $1.3 million of stock compensation expense during the quarter ended June 30, 2012.

StockBased_Compensation

Stock-Based Compensation	6 Months Ended
	Sep. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
STOCK-BASED COMPENSATION	'
	STOCK-BASED COMPENSATION
	The Company accounts for stock-based compensation activity using the modified prospective method. This method requires companies to estimate the fair value of stock-based compensation on the date of grant using an option-pricing model. The Company uses the Black-Scholes model to value stock-based compensation, excluding RSUs, for which the Company uses the fair market value of our common stock. The Black-Scholes model determines the fair value of share-based payment awards based on the stock price on the date of grant and is affected by assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, the Company’s stock price, volatility over the term of the awards and actual and projected employee stock option exercise behaviors. Option-pricing models were developed for use in estimating the value of traded options that have no vesting or hedging restrictions and are fully transferable. Although the fair value of stock options granted by the Company is estimated by the Black-Scholes model, the estimated fair value may not be indicative of the fair value observed in a willing buyer/willing seller market transaction.
	The fair value of the options and employee stock purchase rights granted is estimated as of the grant date using the Black-Scholes option-pricing model with the following weighted-average assumptions:
		ESPP
		Three months ended September 30,
		2013			2012
	Expected life (years)	0.5			0.5
	Risk-free interest rate	0.1		%	0.2		%
	Volatility	57		%	50		%
	Dividend yield	—		%	—		%
	Weighted average fair value	$	3.67		$	1.5
	The Company did not grant options during the three months ended September 30, 2013 and 2012.
		Six Months Ended September 30,
		Employee Stock						ESPP
		Options
		2013			2012			2013			2012
	Expected life (years)	4.4			4.5			0.5			0.5
	Risk-free interest rate	0.6		%	0.7		%	0.1		%	0.2		%
	Volatility	49		%	54		%	57		%	50		%
	Dividend yield	—		%	—		%	—		%	—		%
	Weighted average fair value	$	2.95		$	2.47		$	3.67		$	1.5
	The weighted average grant-date fair value per share of the restricted stock units awarded was $11.97 and $8.00 during the three and six months ended September 30, 2013, respectively, compared to $5.75 and $5.52 during the three and six months ended September 30, 2012, respectively. The weighted average fair value per share was calculated based on the fair market value of the Company’s common stock on the respective grant dates.
	Effective April 1, 2013, the Company revised its estimated forfeiture rate used in determining the amount of stock-based compensation from 6.6% to 6.7% as a result of an increased rate of forfeitures in recent periods, which the Company believes is indicative of the rate it will experience during the remaining vesting period of currently outstanding unvested grants.
	The following table summarizes stock-based compensation expense related to stock options and RSUs (in thousands):
		Three Months Ended						Six Months Ended
		September 30,						September 30,
		2013			2012			2013			2012
	Stock-based compensation expense by type of award
	Stock options	$	737		$	601		$	1,339		$	2,089
	Restricted stock units	3,099			7,031			6,223			13,151
	Total stock-based compensation	3,836			7,632			7,562			15,240
	Stock-based compensation (capitalized to) expensed from inventory	(2		)	2			(14		)	83
	Total stock-based compensation expense	$	3,834		$	7,634		$	7,548		$	15,323
	The following table summarizes stock-based compensation expense as it relates to the Company’s Condensed Consolidated Statement of Operations (in thousands):
		Three Months Ended						Six Months Ended
		September 30,						September 30,
		2013			2012			2013			2012
	Stock-based compensation expense by cost centers
	Cost of revenues	$	127		$	175		$	235		$	355
	Research and development	1,524			3,714			3,322			7,919
	Selling, general and administrative	2,185			3,743			4,005			6,966
	Total stock-based compensation	$	3,836		$	7,632		$	7,562		$	15,240
	Stock-based compensation (capitalized to) expensed from inventory	(2		)	2			(14		)	83
	Total stock-based compensation expense	$	3,834		$	7,634		$	7,548		$	15,323
	The amount of unrecognized stock-based compensation cost currently estimated to be expensed from now through fiscal 2018, including time and performance based awards that are expected to vest, at September 30, 2013 is $17.9 million which will be recognized over a weighted-average period of 1.7 years. If there are any modifications or cancellations of the underlying unvested securities, the Company may be required to accelerate, increase or cancel any remaining unearned stock-based compensation expense. Future stock-based compensation expense and unearned stock-based compensation will increase to the extent that the Company grants additional equity awards or assumes unvested equity awards in connection with acquisitions.
	The stock based compensation expense of approximately $15.3 million for the six months ended September 30, 2012 does not include approximately $1.3 million of expense related to the acceleration of Veloce warrants. See Note 4, Veloce, to the Condensed Consolidated Financial Statements for further details relating to the Veloce warrants.

Contingencies

Contingencies	6 Months Ended
	Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]	'
CONTINGENCIES	'
	CONTINGENCIES
	Legal Proceedings
	The Company is currently a party to certain legal proceedings, including those noted in this section. While the Company presently believes that the ultimate outcome of these proceedings, individually and in the aggregate, will not materially harm the Company's financial position, results of operations, cash flows, or overall trends, legal proceedings are subject to inherent uncertainties, unfavorable rulings or other events that could occur. In addition, legal proceedings are expensive to prosecute and defend against and can divert Management attention and Company resources away from the Company's business objectives. Unfavorable resolutions could include monetary damages against the Company, or preclude the Company from recovering the damages it seeks in legal proceedings it has commenced. It is also possible that the Company could conclude it is in the best interests of its stockholders, employees, and customers to settle one or more such matters, and any such settlement could include substantial payments or the surrender of rights to collect substantial payments from third parties. However, the Company has not reached this conclusion with respect to any particular matter at this time.
	In 1993, the Company was named as a Potentially Responsible Party (“PRP”) along with more than 100 other companies that used an Omega Chemical Corporation waste treatment facility in Whittier, California (the “Omega Site”). The U.S. Environmental Protection Agency (“EPA”) has alleged that Omega failed to properly treat and dispose of certain hazardous waste materials at the Omega Site. The Company is a member of a large group of PRPs, known as the Omega Chemical Site PRP Organized Group (“OPOG”) that has agreed to fund certain on-going remediation efforts at the Omega Site. In February 2001, the U.S. District Court for the Central District of California (the “Court”) approved a consent decree between EPA and OPOG to study the contamination and evaluate cleanup options at the Omega Site (the Operable Unit 1 or “OU1”). In January 2009, the Court approved two amendments to the consent decree, the first expanding the scope of work to mitigate volatile organic compounds affecting indoor air quality near the Omega Site (the Operable Unit 3 or “OU3”) and the second adding settling parties to the consent decree. Removal of waste materials from the Omega Site has been completed. As part of OU1 and OU3, efforts to remediate the soil and groundwater at the Omega Site, as well as the extraction of chemical vapors from the soil and improving indoor air quality in and around the site, are underway and are expected to be ongoing for several years. In addition, OPOG and EPA are investigating a regional groundwater contamination plume allegedly originating at the Omega Site (the Operable Unit 2 or “OU2”). In September 2011, EPA issued an interim Record of Decision specifying the interim clean-up actions EPA has chosen for OU2, and in September 2012, it issued a special notice letter that triggered the commencement of good faith settlement negotiations with OPOG. In July 2013, the EPA rejected a good faith settlement offer that OPOG had submitted in February 2013. Settlement negotiations between the parties are expected to continue through fiscal year 2014. It is anticipated that such settlement negotiations will result in EPA and OPOG entering into a remediation consent decree with the Court regarding OU2. OPOG is expected to vote in December 2013 on whether to retain legal counsel to pursue claims against other potentially responsible parties for the regional groundwater contamination. In November 2007, Angeles Chemical Company, located downstream from the Omega Site, filed a lawsuit (the “Angeles Litigation”) in the Court against OPOG and the PRPs for cost recovery and indemnification for future response costs allegedly resulting from the regional groundwater contamination plume described above. In March 2008, the Court granted OPOG’s motion to stay the Angeles Litigation pending EPA’s determination of how to investigate and remediate the regional groundwater. In January 2012, as a result of challenges made by certain PRPs to the criteria previously used to allocate liability among OPOG members, and of the departure of certain PRPs from OPOG, OPOG approved changes to the cost allocation structure that resulted in an increase to the Company’s proportional allocation of liability. In addition, the subsequent departure of one or more other PRPs from OPOG could have the effect of increasing the proportional liability of the remaining PRPs, including the Company. Although the Company considers a loss relating to the Omega Site probable, its share of any financial obligations for the remediation of the Omega Site, including taking into account the allocation increases described above, is not currently believed to be material to the Company’s financial statements, based on the Company’s approximately 0.5% contribution to the total waste tonnage sent to the site and current estimates of the potential mediation costs. Based on currently available information, the Company has a loss accrual that is not material and believes that the actual amount of its costs will not be materially different from the amount accrued. However, proceedings are ongoing and the eventual outcome of the clean-up efforts and the pending litigation matters is uncertain at this time. Based on currently available information, the Company does not believe that any eventual outcome will have a material adverse effect on its operations.
	In August 2013, a complaint was filed against the Company in the California Superior Court for Santa Clara County by Emulex Corporation (“Emulex”), a purchaser of certain Company products, alleging rights to indemnification by the Company for unspecified expenses incurred by Emulex in connection with patent infringement litigation brought against Emulex by Broadcom Corporation in 2009 and 2010. In September 2013, the Company filed an answer which, among other things, denied each of the allegations in the complaint and filed a cross complaint against Emulex seeking, among other things, damages for fraudulent inducement and a declaratory judgment that the Company has no duty to indemnify Emulex in the Broadcom litigation. Discovery has not yet commenced in these actions.

Sale_of_TPack_AS

Sale of TPack A/S	6 Months Ended
	Sep. 30, 2013
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]	'
	Sale of TPack A/S
	On April 22, 2013, the Company completed the sale of TPack and certain specified intellectual property assets owned by the Company related to TPack's business for an aggregate consideration of $33.5 million, payable in cash, which reflects the $34.0 million base purchase price as adjusted for the working capital adjustment mechanism set forth in the Purchase Agreement, and remains subject to a potential final, non-material post-closing adjustments. In connection with the closing, there was a working capital adjustment of $0.5 million and the Company received a cash payment of $30.2 million. The remaining cash payment of $3.4 million of the aggregate consideration will be held back until March 31, 2014 to secure the Company's indemnification obligations subject to and in accordance with the terms of the Purchase Agreement. The distribution of this holdback amount is subject to any indemnification claims that the buyer may have under the terms of the Purchase Agreement and final resolution of any such claims.
	TPack operated as part of the Company's Connectivity reporting unit. The sale of TPack does not represent an exit from the Connectivity business. The Company will continue to sell Connectivity technology products as an ongoing part of its business, and as such the sale of TPack is not a discontinuance of an operation.
	In connection with the divestiture, we recorded a preliminary gain of $19.7 million. The following table summarizes the components of the gain (in thousands):
	Total proceeds, net of working capital adjustment,	$	30,175
	Net assets and liabilities	(184		)
	Goodwill write off	(1,757		)
	Intangibles write off	(11,404		)
	Holdback amount	3,353
	Legal fees and other costs	(484		)
	Gain on sale of TPack	$	19,699
	The total assets of TPack included $0.7 million of cash, cash equivalents and short term investments.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Basis of Presentation	'
	The Condensed Consolidated Financial Statements include all the accounts of AppliedMicro (the "Company") and its wholly-owned subsidiaries including Veloce Technologies Inc. (“Veloce”), which was consolidated in prior accounting periods prior to its merger with the Company, as a variable interest entity (“VIE”) since the Company was determined to be its primary beneficiary. On June 20, 2012, the Company completed the acquisition of Veloce which became a wholly owned subsidiary of the Company as of this date. See Note 4, Veloce, to the Condensed Consolidated Financial Statements. All significant intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates	'
	The preparation of financial statements in accordance with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of net revenue and expenses in the reporting period. The Company regularly evaluates estimates and assumptions related to its:
	•	capitalized mask sets including its useful lives, which affects cost of goods sold and property and equipment or Research and Development ("R&D") expenses, if not capitalized;
	•	inventory valuation, warranty liabilities and revenue reserves, which affects cost of sales, gross margin, and revenues;
	•	allowance for doubtful accounts, which affects operating expenses;
	•	unrealized losses or other-than-temporary impairments of short-term investments available for sale, which affects interest income (expense), net;
	•	valuation of purchased intangibles and goodwill, which affects amortization and impairments of purchased intangibles, impairments of goodwill and apportionment of goodwill related to divestitures;
	•	Veloce accrued liability which considers: (i) estimating the total value of the expected Veloce consideration, (ii) determining the stage at which a milestone is deemed to be probable of attainment, (iii) the estimated progress towards achieving the milestone at the time such milestone was deemed probable of achievement and (iv) estimating the approximate timing of the expected completion of the milestones and related payments;
	•	potential costs of litigation, which affects operating expenses;
	•	valuation of deferred income taxes, which affects income tax expense (benefit); and
	•	stock-based compensation, which affects gross margin and operating expenses.
	The Company bases its estimates and assumptions on historical experience and on various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from management’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.

Certain_Financial_Statement_In1

Certain Financial Statement Information (Tables)	6 Months Ended
	Sep. 30, 2013
Certain Financial Statement Information [Abstract]	'
Schedule of Accounts receivable	'
	Accounts receivable:
			September 30,				March 31,
			2013				2013
			(In thousands)
	Accounts receivable		$	27,165			$	25,278
	Less: allowance for bad debts		(458		)		(703		)
			$	26,707			$	24,575
Schedule of Inventories	'
	Inventories:
			September 30,				March 31,
			2013				2013
			(In thousands)
	Finished goods		$	5,802			$	7,247
	Work in process		4,778				4,098
	Raw materials		2,215				1,555
			$	12,795			$	12,900
Schedule of Other current assets	'
	Other current assets:
			September 30,				March 31,
			2013				2013
			(In thousands)
	Prepaid expenses		$	12,321			$	13,762
	Executive deferred compensation assets		1,075				693
	Deposits		652				828
	Receivable from sale of strategic investment and TPack		3,353				1,331
	Other		1,994				1,384
			$	19,395			$	17,998
Schedule of Property and equipment	'
	Property and equipment:
			Useful		September 30,				March 31,
			Life		2013				2013
			(In years)		(In thousands)
	Machinery and equipment *		7-May		$	44,900			$	40,063
	Leasehold improvements		15-Jan		11,480				14,202
	Computers, office furniture and equipment		7-Mar		43,845				43,485
	Buildings		31.5		2,756				2,756
	Land		—		9,800				9,800
					112,781				110,306
	Less: accumulated depreciation and amortization				(78,789		)		(75,915		)
					$	33,992			$	34,391
	* Includes capitalized mask costs.
Schedule of Goodwill	'
	Goodwill is as follows:
		September 30,				March 31,
		2013				2013
		(In thousands)
	Goodwill	$	11,425			$	13,183
Schedule of Purchased intangible assets	'
	Purchase-related intangibles were as follows:
			30-Sep-13															31-Mar-13
			Gross				Accumulated				Net				Weighted			Gross			Accumulated				Net			Weighted
							Amortization								average						Amortization							average
							and Impairments								remaining						and Impairments							remaining
															useful life													useful life
			(In thousands)												(In years)			(In thousands)										(In years)
	Developed technology/in-process research and development		$	425,000			$	(425,000	)		$	—			—			$	441,300		$	(431,771	)		$	9,529		3.5
	Customer relationships		6,330				(6,101		)		229				0.9			12,830			(10,507		)		2,323			2.1
	Patents/core technology rights/tradename		62,306				(62,306		)		—				—			63,206			(63,067		)		139			0.3
			$	493,636			$	(493,407	)		$	229						$	517,336		$	(505,345	)		$	11,991
	During the quarter ended June 30, 2013, $11.4 million of purchased intangibles were written off pursuant to the sale of TPack. Please refer to Note 8, Sale of TPack A/S, to the Condensed Consolidated Financial Statements for further discussion.
Schedule of Estimated future amortization expense of purchased intangible assets	'
	As of September 30, 2013, the estimated future amortization expense of purchased intangible assets to be charged to operating expenses was as follows (in thousands):
			Operating
			Expenses
	Fiscal Years Ending March 31,
	2014 (remainder of year)		$	125
	2015		104
	2016 and thereafter		—
	Total		$	229
Schedule of Other assets	'
	Other assets:
			September 30,				March 31,
			2013				2013
			(In thousands)
	Non-current portion of prepaid expenses		$	5,650			$	7,866
	Strategic investments		3,000				3,000
			$	8,650			$	10,866
Schedule of Other accrued liabilities	'
	Other accrued liabilities:
			September 30,				March 31,
			2013				2013
			(In thousands)
	Employee related liabilities		$	2,168			$	2,236
	Executive deferred compensation		1,310				1,284
	Income taxes		1,127				903
	Professional fees		3,977				3,840
	Other		4,482				2,467
			$	13,064			$	10,730
Schedule of Cash, cash equivalents and available-for-sale investments by type of instruments	'
	The following is a summary of cash, cash equivalents and available-for-sale investments by type of instrument (in thousands):
			30-Sep-13																31-Mar-13
			Amortized				Gross Unrealized								Estimated				Amortized			Gross Unrealized							Estimated
			Cost				Gains				Losses				Fair Value				Cost			Gains				Losses			Fair Value
	Cash		$	20,652			$	—			$	—			$	20,652			$	8,529		$	—			$	—		$	8,529
	Cash equivalents		7,256				—				—				7,256				10,536			—				—			10,536
	U.S. Treasury securities and agency bonds		12,400				12				2				12,410				12,363			10				—			12,373
	Corporate bonds		11,927				45				1				11,971				15,567			63				2			15,628
	Mortgage-backed and asset-backed securities*		4,144				339				25				4,458				3,655			355				7			4,003
	Closed-end bond funds		14,374				2,120				530				15,964				21,914			5,340				39			27,215
	Preferred stock		2,406				851				—				3,257				4,878			2,314				—			7,192
			$	73,159			$	3,367			$	558			$	75,968			$	77,442		$	8,082			$	48		$	85,476
	Reported as:
	Cash and cash equivalents														$	27,908													$	19,065
	Short-term investments available-for-sale														48,060														66,411
															$	75,968													$	85,476
	* At September 30, 2013 and March 31, 2013, approximately $1.2 million and $1.4 million of the estimated fair value presented were mortgage-backed securities, respectively.
Schedule of Cash, cash equivalents and available-for-sale investments by type of instruments measured at fair value on recurring basis	'
	The following is a summary of cash, cash equivalents and available-for-sale investments by type of instrument measured at fair value on a recurring basis (in thousands):
			30-Sep-13																31-Mar-13
			Level 1				Level 2				Level 3				Total				Level 1			Level 2				Level 3			Total
	Cash		$	20,652			$	—			$	—			$	20,652			$	8,529		$	—			$	—		$	8,529
	Cash equivalents		7,156				100				—				7,256				9,508			1,028				—			10,536
	U.S. Treasury securities and agency bonds		11,951				459				—				12,410				12,373			—				—			12,373
	Corporate bonds		—				11,971				—				11,971				—			15,628				—			15,628
	Mortgage-backed and asset-backed securities		—				4,458				—				4,458				—			4,003				—			4,003
	Closed-end bond funds		15,964				—				—				15,964				27,215			—				—			27,215
	Preferred stock		—				3,257				—				3,257				—			7,192				—			7,192
			$	55,723			$	20,245			$	—			$	75,968			$	57,625		$	27,851			$	—		$	85,476
Schedule of Cost and estimated fair values of available-for-sale securities with stated maturities by contractual maturity	'
	The following is a summary of the cost and estimated fair values of available-for-sale securities with stated maturities, which include U.S. Treasury securities and agency bonds, corporate bonds and mortgage-backed and asset-backed securities, by contractual maturity (in thousands):
			30-Sep-13								31-Mar-13
			Cost				Fair Value				Cost				Fair Value
	Less than 1 year		$	7,867			$	8,040			$	9,205			$	9,217
	Mature in 1 – 2 years		19,341				19,386				19,843				20,040
	Mature in 3 – 5 years		353				446				1,575				1,649
	Mature after 5 years		910				967				962				1,098
			$	28,471			$	28,839			$	31,585			$	32,004
Schedule of Gross unrealized losses	'
	The following is a summary of gross unrealized losses as of (in thousands):
			Less Than 12 Months of								12 Months or More of								Total
			Unrealized Losses								Unrealized Losses
	As of September 30, 2013		Estimated				Gross				Estimated				Gross				Estimated			Gross
			Fair				Unrealized				Fair				Unrealized				Fair			Unrealized
			Value				Losses				Value				Losses				Value			Losses
	U.S. Treasury securities and agency bonds		$	1,468			$	(2	)		$	—			$	—			$	1,468		$	(2	)
	Corporate bonds		1,654				(1		)		—				—				1,654			(1		)
	Mortgage-backed and asset-backed securities		1,675				(25		)		12				—				1,687			(25		)
	Closed-end bond funds		4,705				(448		)		391				(82		)		5,096			(530		)
			$	9,502			$	(476	)		$	403			$	(82	)		$	9,905		$	(558	)
			Less Than 12 Months of								12 Months or More of								Total
			Unrealized Losses								Unrealized Losses
	As of March 31, 2013		Estimated				Gross				Estimated				Gross				Estimated			Gross
			Fair				Unrealized				Fair				Unrealized				Fair			Unrealized
			Value				Losses				Value				Losses				Value			Losses
	U.S. Treasury securities and agency bonds		$	300			$	—			$	—			$	—			$	300		$	—
	Corporate bonds		2,276				(2		)		113				—				2,389			(2		)
	Mortgage-backed and asset-backed securities		647				(3		)		—				(4		)		647			(7		)
	Closed-end bond funds		—				—				6,991				(39		)		6,991			(39		)
			$	3,223			$	(5	)		$	7,104			$	(43	)		$	10,327		$	(48	)
Schedule of Warranty reserve activity	'
	The following table summarizes warranty reserve activity (in thousands):
		Three Months Ended								Six months ended
		September 30,								September 30,
		2013				2012				2013				2012
	Beginning balance	$	203			$	447			$	220			$	454
	Charged to costs of revenues	(11		)		85				(26		)		215
	Cost incurred	(5		)		(162		)		(7		)		(299		)
	Ending balance	$	187			$	370			$	187			$	370
Schedule of Interest income, net	'
	Interest income (expense), net (in thousands):
			Three Months Ended								Six months ended
			September 30,								September 30,
			2013				2012				2013				2012
	Interest income		$	402			$	568			$	870			$	1,230
	Net realized gain on short-term investments		86				177				3,284				1,194
			$	488			$	745			$	4,154			$	2,424
Schedule of Reconciliation of shares used to calculate basic and diluted net loss per share	'
	The reconciliation of shares used to calculate basic and diluted net loss per share consists of the following (in thousands, except per share data):
			Three Months Ended								Six months ended
			September 30,								September 30,
			2013				2012				2013				2012
	Net loss		$	(32,383	)		$	(21,557	)		$	(21,526	)		$	(44,947	)
	Shares used in net loss per share computation:
	Weighted average common shares outstanding, basic		72,610				64,947				70,985				63,678
	Net effect of dilutive common share equivalents		—				—				—				—
	Weighted average common shares outstanding, diluted		72,610				64,947				70,985				63,678
	Basic and diluted net loss per share		$	(0.45	)		$	(0.33	)		$	(0.30	)		$	(0.71	)

Restructuring_Charges_Tables

Restructuring Charges (Tables)	6 Months Ended
	Sep. 30, 2013
Restructuring and Related Activities [Abstract]	'
Schedule of restructuring activity	'
	The restructuring activity during the six months ended September 30, 2013 relating to the December 2012 and August 2013 restructuring programs is as follows (in thousands):
		Workforce Reduction			Asset Impairment			Total
	Liability, March 31, 2013	$	548		$	—		$	548
	Restructuring charges	93			—			$	93
	Cash payments	(334		)	—			$	(334	)
	Liability, June 30, 2013	307			—			307
	Restructuring charges	727			272			999
	Non-cash items	—			(272		)	(272		)
	Cash payments	(847		)	—			(847		)
	Liability, September 30, 2013	$	187		$	—		$	187

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	6 Months Ended
	Sep. 30, 2013
Stockholders' Equity Note [Abstract]	'
Schedule of Option Activity Under Stock Incentive Plans	'
	Option activity under the Company’s stock incentive plans during the six months ended September 30, 2013 is set forth below (in thousands, except per share data):
			Number of Shares		Weighted Average
					Exercise Price
					Per Share
	Outstanding at the beginning of the year		3,492		$	10.26
	Granted		40		7.35
	Exercised		(495	)	8.97
	Cancelled		(367	)	10.15
	Outstanding at the end of the period		2,670		$	10.47
	Vested and expected to vest at the end of the period		2,667		$	10.47
	Vested and exercisable at the end of the period		2,512		$	10.56
Weighted Average Remaining Contractual Life and Weighted Average Per Share Exercise Price of Options Outstanding and Options Exercisable	'
	The weighted average remaining contractual life and weighted average per share exercise price of options outstanding and of options exercisable as of September 30, 2013 were as follows (in thousands, except exercise prices and years):
			Options Outstanding						Options Exercisable
	Range of Exercise Prices		Number of		Weighted		Weighted		Number of	Weighted
			Shares		Average		Average		Shares	Average
					Remaining		Exercise Price			Exercise Price
					Contractual
					Life
	$  1.68 - $ 7.60		570		3.54		$	6.69	472	$	6.58
	7.61 - 7.67		650		2.84		7.67		650	7.67
	7.68 - 11.86		469		3.6		10.45		431	10.34
	11.87 - 14.20		599		2.63		12.78		577	12.81
	14.21 - 23.32		382		1.61		17.26		382	17.26
	$  1.68 - $23.32		2,670		2.9		$	10.47	2,512	$	10.56
Schedule of Restricted Stock Unit Activity	'
	Restricted stock unit activity during the six months ended September 30, 2013 is set forth below (in thousands):
		Number of Shares
	Outstanding at the beginning of the year	6,444
	Awarded	2,032
	Vested	(1,649	)
	Cancelled	(1,452	)
	Outstanding at the end of the period	5,375

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	6 Months Ended
	Sep. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Weighted-Average Assumptions Used to Estimate the Fair Value of Stock Options	'
	The fair value of the options and employee stock purchase rights granted is estimated as of the grant date using the Black-Scholes option-pricing model with the following weighted-average assumptions:
		ESPP
		Three months ended September 30,
		2013			2012
	Expected life (years)	0.5			0.5
	Risk-free interest rate	0.1		%	0.2		%
	Volatility	57		%	50		%
	Dividend yield	—		%	—		%
	Weighted average fair value	$	3.67		$	1.5
	The Company did not grant options during the three months ended September 30, 2013 and 2012.
		Six Months Ended September 30,
		Employee Stock						ESPP
		Options
		2013			2012			2013			2012
	Expected life (years)	4.4			4.5			0.5			0.5
	Risk-free interest rate	0.6		%	0.7		%	0.1		%	0.2		%
	Volatility	49		%	54		%	57		%	50		%
	Dividend yield	—		%	—		%	—		%	—		%
	Weighted average fair value	$	2.95		$	2.47		$	3.67		$	1.5
Summary of Stock-Based Compensation Expense of Stock Options and Restricted Stock Units	'
	The following table summarizes stock-based compensation expense related to stock options and RSUs (in thousands):
		Three Months Ended						Six Months Ended
		September 30,						September 30,
		2013			2012			2013			2012
	Stock-based compensation expense by type of award
	Stock options	$	737		$	601		$	1,339		$	2,089
	Restricted stock units	3,099			7,031			6,223			13,151
	Total stock-based compensation	3,836			7,632			7,562			15,240
	Stock-based compensation (capitalized to) expensed from inventory	(2		)	2			(14		)	83
	Total stock-based compensation expense	$	3,834		$	7,634		$	7,548		$	15,323
Summary of Stock-Based Compensation Expense	'
	The following table summarizes stock-based compensation expense as it relates to the Company’s Condensed Consolidated Statement of Operations (in thousands):
		Three Months Ended						Six Months Ended
		September 30,						September 30,
		2013			2012			2013			2012
	Stock-based compensation expense by cost centers
	Cost of revenues	$	127		$	175		$	235		$	355
	Research and development	1,524			3,714			3,322			7,919
	Selling, general and administrative	2,185			3,743			4,005			6,966
	Total stock-based compensation	$	3,836		$	7,632		$	7,562		$	15,240
	Stock-based compensation (capitalized to) expensed from inventory	(2		)	2			(14		)	83
	Total stock-based compensation expense	$	3,834		$	7,634		$	7,548		$	15,323

Sale_of_TPack_AS_Tables

Sale of TPack A/S (Tables)	6 Months Ended
	Sep. 30, 2013
Discontinued Operations and Disposal Groups [Abstract]	'
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]	'
	In connection with the divestiture, we recorded a preliminary gain of $19.7 million. The following table summarizes the components of the gain (in thousands):
	Total proceeds, net of working capital adjustment,	$	30,175
	Net assets and liabilities	(184		)
	Goodwill write off	(1,757		)
	Intangibles write off	(11,404		)
	Holdback amount	3,353
	Legal fees and other costs	(484		)
	Gain on sale of TPack	$	19,699

Certain_Financial_Statement_In2

Certain Financial Statement Information (Details) (USD $)	Sep. 30, 2013	Mar. 31, 2013
In Thousands, unless otherwise specified
Schedule of Accounts receivable	'	'
Accounts receivable	$27,165	$25,278
Less: allowance for bad debts	-458	-703
Accounts receivable, net	$26,707	$24,575	[1]
[1]	Amounts have been derived from the March 31, 2013 audited consolidated financial statements.

Certain_Financial_Statement_In3

Certain Financial Statement Information (Details 1) (USD $)	Sep. 30, 2013	Mar. 31, 2013
In Thousands, unless otherwise specified
Schedule of Inventories	'	'
Finished goods	$5,802	$7,247
Work in process	4,778	4,098
Raw materials	2,215	1,555
Inventories, total	$12,795	$12,900	[1]
[1]	Amounts have been derived from the March 31, 2013 audited consolidated financial statements.

Certain_Financial_Statement_In4

Certain Financial Statement Information (Details 2) (USD $)	Sep. 30, 2013	Mar. 31, 2013
In Thousands, unless otherwise specified
Schedule of Other current assets	'	'
Prepaid expenses	$12,321	$13,762
Executive deferred compensation assets	1,075	693
Deposits	652	828
Receivable from sale of strategic investment and TPack	3,353	1,331
Other	1,994	1,384
Other current assets, total	$19,395	$17,998	[1]
[1]	Amounts have been derived from the March 31, 2013 audited consolidated financial statements.

Certain_Financial_Statement_In5

Certain Financial Statement Information (Details 3) (USD $)	Sep. 30, 2013		Mar. 31, 2013		Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013
In Thousands, unless otherwise specified					Machinery and Equipment [Member]	Machinery and Equipment [Member]	Leasehold Improvements [Member]	Leasehold Improvements [Member]	Computers, Office Furniture and Equipment [Member]	Computers, Office Furniture and Equipment [Member]	Buildings [Member]
					Minimum [Member]	Maximum [Member]	Minimum [Member]	Maximum [Member]	Minimum [Member]	Maximum [Member]
Schedule of Property and equipment	'		'		'	'	'	'	'	'	'
Useful life	'		'		'5 years	'7 years	'1 year	'15 years	'3 years	'7 years	'31 years 6 months
Machinery and equipment	$44,900	[1]	$40,063	[1]	'	'	'	'	'	'	'
Leasehold improvements	11,480		14,202		'	'	'	'	'	'	'
Computers, office furniture and equipment	43,845		43,485		'	'	'	'	'	'	'
Buildings	2,756		2,756		'	'	'	'	'	'	'
Land	9,800		9,800		'	'	'	'	'	'	'
Property and equipment, gross	112,781		110,306		'	'	'	'	'	'	'
Less: accumulated depreciation and amortization	-78,789		-75,915		'	'	'	'	'	'	'
Property and equipment, net	$33,992		$34,391	[2]	'	'	'	'	'	'	'
[1]	Includes capitalized mask costs.
[2]	Amounts have been derived from the March 31, 2013 audited consolidated financial statements.

Certain_Financial_Statement_In6

Certain Financial Statement Information (Details 4) (USD $)	Sep. 30, 2013	Mar. 31, 2013		Sep. 30, 2013
In Thousands, unless otherwise specified				TPack [Member]
Schedule of Goodwill	'	'		'
Goodwill	$11,425	$13,183	[1]	'
Goodwill write off	'	'		$1,757
[1]	Amounts have been derived from the March 31, 2013 audited consolidated financial statements.

Certain_Financial_Statement_In7

Certain Financial Statement Information (Details 5) (USD $)	Sep. 30, 2013	Mar. 31, 2013	Apr. 22, 2013	Sep. 30, 2013	Sep. 30, 2013		Mar. 31, 2013	Sep. 30, 2013	Mar. 31, 2013	Sep. 30, 2013	Mar. 31, 2013
In Thousands, unless otherwise specified			TPack [Member]	TPack [Member]	Developed technology/in-process research and development [Member]		Developed technology/in-process research and development [Member]	Customer relationships [Member]	Customer relationships [Member]	Patents/core technology rights/tradename [Member]	Patents/core technology rights/tradename [Member]
Schedule of Purchased Intangible assets	'	'	'	'	'		'	'	'	'	'
Gross Assets	$493,636	$517,336	'	'	$425,000	[1]	$441,300	$6,330	$12,830	$62,306	$63,206
Accumulated Amortization and Impairments	-493,407	-505,345	'	'	-425,000	[1]	-431,771	-6,101	-10,507	-62,306	-63,067
Net Assets	229	11,991	'	'	0	[1]	9,529	229	2,323	0	139
Weighted average remaining useful life	'	'	'	'	'0 years	[1]	'3 years 6 months	'10 months 12 days	'2 years 1 month 6 days	'0 years	'3 months 18 days
Intangibles write off	'	'	($11,404)	$11,400	'		'	'	'	'	'
[1]	During the quarter ended June 30, 2013, $11.4 million of purchased intangibles were written off pursuant to the sale of TPack. Please refer to Note 8, Sale of TPack A/S, to the Condensed Consolidated Financial Statements for further discussion.

Certain_Financial_Statement_In8

Certain Financial Statement Information (Details 6) (Operating Expenses [Member], USD $)	Sep. 30, 2013
In Thousands, unless otherwise specified
Operating Expenses [Member]	'
Schedule of Estimated Future Amortization Expense [Line Items]	'
2014 (remainder of year)	$125
2015	104
2016 and thereafter	0
Total	$229

Certain_Financial_Statement_In9

Certain Financial Statement Information (Details 7) (USD $)	Sep. 30, 2013	Mar. 31, 2013
In Thousands, unless otherwise specified
Schedule of other assets	'	'
Non-current portion of prepaid expenses	$5,650	$7,866
Strategic investments	3,000	3,000
Total other assets	$8,650	$10,866	[1]
[1]	Amounts have been derived from the March 31, 2013 audited consolidated financial statements.

Recovered_Sheet1

Certain Financial Statement Information (Details 8) (USD $)	Sep. 30, 2013	Mar. 31, 2013
In Thousands, unless otherwise specified
Schedule of other accrued liabilities	'	'
Employee related liabilities	$2,168	$2,236
Executive deferred compensation	1,310	1,284
Income taxes	1,127	903
Professional fees	3,977	3,840
Other	4,482	2,467
Total other accrued liabilities	$13,064	$10,730	[1]
[1]	Amounts have been derived from the March 31, 2013 audited consolidated financial statements.

Recovered_Sheet2

Certain Financial Statement Information (Details 9) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013		Sep. 30, 2012	Mar. 31, 2013		Mar. 31, 2012
Schedule of Available-for-sale Securities [Line Items]	'		'	'		'
Cost method investment, ownership percentage (less than)	20.00%		'	'		'
Investments in non-marketable equity investments, cost method	$0		$500	'		'
Schedule of cash, cash equivalents and available-for-sale investments by type of instruments	'		'	'		'
Cash, Cash equivalents and Short-term investments, Amortized Cost	73,159		'	77,442		'
Available-for-sale investments, Gross Unrealized Gains	3,367		'	8,082		'
Available-for-sale investments, Gross Unrealized Losses	558		'	48		'
Cash, Cash equivalents and Short-term investments, Estimated Fair Value	75,968		'	85,476		'
Cash and cash equivalents	27,908		11,992	19,065	[1]	28,065
Short-term investments available-for-sale	48,060		'	66,411	[1]	'
Cash [Member]	'		'	'		'
Schedule of cash, cash equivalents and available-for-sale investments by type of instruments	'		'	'		'
Cash, Cash equivalents and Short-term investments, Amortized Cost	20,652		'	8,529		'
Available-for-sale investments, Gross Unrealized Gains	0		'	0		'
Available-for-sale investments, Gross Unrealized Losses	0		'	0		'
Cash and Cash equivalents, Estimated Fair Value	20,652		'	8,529		'
Cash equivalents [Member]	'		'	'		'
Schedule of cash, cash equivalents and available-for-sale investments by type of instruments	'		'	'		'
Cash, Cash equivalents and Short-term investments, Amortized Cost	7,256		'	10,536		'
Available-for-sale investments, Gross Unrealized Gains	0		'	0		'
Available-for-sale investments, Gross Unrealized Losses	0		'	0		'
Cash and Cash equivalents, Estimated Fair Value	7,256		'	10,536		'
U.S Treasury securities and agency bonds [Member]	'		'	'		'
Schedule of cash, cash equivalents and available-for-sale investments by type of instruments	'		'	'		'
Cash, Cash equivalents and Short-term investments, Amortized Cost	12,400		'	12,363		'
Available-for-sale investments, Gross Unrealized Gains	12		'	10		'
Available-for-sale investments, Gross Unrealized Losses	2		'	0		'
Cash, Cash equivalents and Short-term investments, Estimated Fair Value	12,410		'	12,373		'
Corporate bonds [Member]	'		'	'		'
Schedule of cash, cash equivalents and available-for-sale investments by type of instruments	'		'	'		'
Cash, Cash equivalents and Short-term investments, Amortized Cost	11,927		'	15,567		'
Available-for-sale investments, Gross Unrealized Gains	45		'	63		'
Available-for-sale investments, Gross Unrealized Losses	1		'	2		'
Cash, Cash equivalents and Short-term investments, Estimated Fair Value	11,971		'	15,628		'
Mortgage-backed and asset-backed securities [Member]	'		'	'		'
Schedule of cash, cash equivalents and available-for-sale investments by type of instruments	'		'	'		'
Cash, Cash equivalents and Short-term investments, Amortized Cost	4,144		'	3,655		'
Available-for-sale investments, Gross Unrealized Gains	339		'	355		'
Available-for-sale investments, Gross Unrealized Losses	25		'	7		'
Cash, Cash equivalents and Short-term investments, Estimated Fair Value	4,458	[2]	'	4,003	[2]	'
Closed-end bond funds [Member]	'		'	'		'
Schedule of cash, cash equivalents and available-for-sale investments by type of instruments	'		'	'		'
Cash, Cash equivalents and Short-term investments, Amortized Cost	14,374		'	21,914		'
Available-for-sale investments, Gross Unrealized Gains	2,120		'	5,340		'
Available-for-sale investments, Gross Unrealized Losses	530		'	39		'
Cash, Cash equivalents and Short-term investments, Estimated Fair Value	15,964		'	27,215		'
Preferred stock [Member]	'		'	'		'
Schedule of cash, cash equivalents and available-for-sale investments by type of instruments	'		'	'		'
Cash, Cash equivalents and Short-term investments, Amortized Cost	2,406		'	4,878		'
Available-for-sale investments, Gross Unrealized Gains	851		'	2,314		'
Available-for-sale investments, Gross Unrealized Losses	0		'	0		'
Cash, Cash equivalents and Short-term investments, Estimated Fair Value	3,257		'	7,192		'
Mortgage-backed securities [Member]	'		'	'		'
Schedule of cash, cash equivalents and available-for-sale investments by type of instruments	'		'	'		'
Cash, Cash equivalents and Short-term investments, Estimated Fair Value	$1,200	[2]	'	$1,400	[2]	'
[1]	Amounts have been derived from the March 31, 2013 audited consolidated financial statements.
[2]	At September 30, 2013 and March 31, 2013, approximately $1.2 million and $1.4 million of the estimated fair value presented were mortgage-backed securities, respectively.

Recovered_Sheet3

Certain Financial Statement Information (Details 10) (USD $)	Sep. 30, 2013		Mar. 31, 2013
In Thousands, unless otherwise specified
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis	'		'
Cash, cash equivalents and short term investments, measured at fair value on a recurring basis	$75,968		$85,476
Cash, cash equivalents and available-for-sale investments measured at fair value on recurring basis	75,968		85,476
Level 1 [Member]	'		'
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis	'		'
Cash, cash equivalents and available-for-sale investments measured at fair value on recurring basis	55,723		57,625
Level 2 [Member]	'		'
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis	'		'
Cash, cash equivalents and available-for-sale investments measured at fair value on recurring basis	20,245		27,851
Level 3 [Member]	'		'
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis	'		'
Cash, cash equivalents and available-for-sale investments measured at fair value on recurring basis	0		0
Cash [Member]	'		'
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis	'		'
Cash and cash equivalents measured at fair value on a recurring basis	20,652		8,529
Cash [Member] | Level 1 [Member]	'		'
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis	'		'
Cash and cash equivalents measured at fair value on a recurring basis	20,652		8,529
Cash [Member] | Level 2 [Member]	'		'
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis	'		'
Cash and cash equivalents measured at fair value on a recurring basis	0		0
Cash [Member] | Level 3 [Member]	'		'
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis	'		'
Cash and cash equivalents measured at fair value on a recurring basis	0		0
Cash equivalents [Member]	'		'
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis	'		'
Cash and cash equivalents measured at fair value on a recurring basis	7,256		10,536
Cash equivalents [Member] | Level 1 [Member]	'		'
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis	'		'
Cash and cash equivalents measured at fair value on a recurring basis	7,156		9,508
Cash equivalents [Member] | Level 2 [Member]	'		'
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis	'		'
Cash and cash equivalents measured at fair value on a recurring basis	100		1,028
Cash equivalents [Member] | Level 3 [Member]	'		'
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis	'		'
Cash and cash equivalents measured at fair value on a recurring basis	0		0
U.S Treasury securities and agency bonds [Member]	'		'
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis	'		'
Cash, cash equivalents and short term investments, measured at fair value on a recurring basis	12,410		12,373
U.S Treasury securities and agency bonds [Member] | Level 1 [Member]	'		'
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis	'		'
Cash, cash equivalents and short term investments, measured at fair value on a recurring basis	11,951		12,373
U.S Treasury securities and agency bonds [Member] | Level 2 [Member]	'		'
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis	'		'
Cash, cash equivalents and short term investments, measured at fair value on a recurring basis	459		0
U.S Treasury securities and agency bonds [Member] | Level 3 [Member]	'		'
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis	'		'
Cash, cash equivalents and short term investments, measured at fair value on a recurring basis	0		0
Corporate bonds [Member]	'		'
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis	'		'
Cash, cash equivalents and short term investments, measured at fair value on a recurring basis	11,971		15,628
Corporate bonds [Member] | Level 1 [Member]	'		'
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis	'		'
Cash, cash equivalents and short term investments, measured at fair value on a recurring basis	0		0
Corporate bonds [Member] | Level 2 [Member]	'		'
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis	'		'
Cash, cash equivalents and short term investments, measured at fair value on a recurring basis	11,971		15,628
Corporate bonds [Member] | Level 3 [Member]	'		'
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis	'		'
Cash, cash equivalents and short term investments, measured at fair value on a recurring basis	0		0
Mortgage-backed and asset-backed securities [Member]	'		'
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis	'		'
Cash, cash equivalents and short term investments, measured at fair value on a recurring basis	4,458	[1]	4,003	[1]
Mortgage-backed and asset-backed securities [Member] | Level 1 [Member]	'		'
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis	'		'
Cash, cash equivalents and short term investments, measured at fair value on a recurring basis	0		0
Mortgage-backed and asset-backed securities [Member] | Level 2 [Member]	'		'
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis	'		'
Cash, cash equivalents and short term investments, measured at fair value on a recurring basis	4,458		4,003
Mortgage-backed and asset-backed securities [Member] | Level 3 [Member]	'		'
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis	'		'
Cash, cash equivalents and short term investments, measured at fair value on a recurring basis	0		0
Closed-end bond funds [Member]	'		'
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis	'		'
Cash, cash equivalents and short term investments, measured at fair value on a recurring basis	15,964		27,215
Closed-end bond funds [Member] | Level 1 [Member]	'		'
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis	'		'
Cash, cash equivalents and short term investments, measured at fair value on a recurring basis	15,964		27,215
Closed-end bond funds [Member] | Level 2 [Member]	'		'
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis	'		'
Cash, cash equivalents and short term investments, measured at fair value on a recurring basis	0		0
Closed-end bond funds [Member] | Level 3 [Member]	'		'
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis	'		'
Cash, cash equivalents and short term investments, measured at fair value on a recurring basis	0		0
Preferred stock [Member]	'		'
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis	'		'
Cash, cash equivalents and short term investments, measured at fair value on a recurring basis	3,257		7,192
Preferred stock [Member] | Level 1 [Member]	'		'
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis	'		'
Cash, cash equivalents and short term investments, measured at fair value on a recurring basis	0		0
Preferred stock [Member] | Level 2 [Member]	'		'
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis	'		'
Cash, cash equivalents and short term investments, measured at fair value on a recurring basis	3,257		7,192
Preferred stock [Member] | Level 3 [Member]	'		'
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis	'		'
Cash, cash equivalents and short term investments, measured at fair value on a recurring basis	$0		$0
[1]	At September 30, 2013 and March 31, 2013, approximately $1.2 million and $1.4 million of the estimated fair value presented were mortgage-backed securities, respectively.

Recovered_Sheet4

Certain Financial Statement Information (Details 11) (USD $)	Sep. 30, 2013	Mar. 31, 2013
In Thousands, unless otherwise specified
Schedule of cost and estimated fair values of available-for-sale securities with stated maturities by contractual maturity	'	'
Less than 1 year, Cost	$7,867	$9,205
Mature in 1 - 2 years, Cost	19,341	19,843
Mature in 3 - 5 years, Cost	353	1,575
Mature after 5 years, Cost	910	962
Cost, Total	28,471	31,585
Less than 1 year, Fair Value	8,040	9,217
Mature in 1 - 2 years, Fair Value	19,386	20,040
Mature in 3 - 5 years, Fair Value	446	1,649
Mature after 5 years, Fair Value	967	1,098
Fair Value, Total	$28,839	$32,004

Recovered_Sheet5

Certain Financial Statement Information (Details 12) (USD $)	Sep. 30, 2013	Mar. 31, 2013
In Thousands, unless otherwise specified
Schedule of Gross Unrealized Losses	'	'
Less Than 12 Months of Unrealized Losses, Estimated Fair Value	$9,502	$3,223
Less Than 12 Months of Unrealized Losses, Gross Unrealized Losses	-476	-5
12 Months or More of Unrealized Losses, Estimated Fair Value	403	7,104
12 Months or More of Unrealized Losses, Gross Unrealized Losses	-82	-43
Total, Estimated Fair Value	9,905	10,327
Total, Gross Unrealized Losses	-558	-48
Gross unrealized gains	3,367	8,082
U.S Treasury securities and agency bonds [Member]	'	'
Schedule of Gross Unrealized Losses	'	'
Less Than 12 Months of Unrealized Losses, Estimated Fair Value	1,468	300
Less Than 12 Months of Unrealized Losses, Gross Unrealized Losses	-2	0
12 Months or More of Unrealized Losses, Estimated Fair Value	0	0
12 Months or More of Unrealized Losses, Gross Unrealized Losses	0	0
Total, Estimated Fair Value	1,468	300
Total, Gross Unrealized Losses	-2	0
Gross unrealized gains	12	10
Corporate bonds [Member]	'	'
Schedule of Gross Unrealized Losses	'	'
Less Than 12 Months of Unrealized Losses, Estimated Fair Value	1,654	2,276
Less Than 12 Months of Unrealized Losses, Gross Unrealized Losses	-1	-2
12 Months or More of Unrealized Losses, Estimated Fair Value	0	113
12 Months or More of Unrealized Losses, Gross Unrealized Losses	0	0
Total, Estimated Fair Value	1,654	2,389
Total, Gross Unrealized Losses	-1	-2
Gross unrealized gains	45	63
Mortgage-backed and asset-backed securities [Member]	'	'
Schedule of Gross Unrealized Losses	'	'
Less Than 12 Months of Unrealized Losses, Estimated Fair Value	1,675	647
Less Than 12 Months of Unrealized Losses, Gross Unrealized Losses	-25	-3
12 Months or More of Unrealized Losses, Estimated Fair Value	12	0
12 Months or More of Unrealized Losses, Gross Unrealized Losses	0	-4
Total, Estimated Fair Value	1,687	647
Total, Gross Unrealized Losses	-25	-7
Gross unrealized gains	339	355
Closed-end bond funds [Member]	'	'
Schedule of Gross Unrealized Losses	'	'
Less Than 12 Months of Unrealized Losses, Estimated Fair Value	4,705	0
Less Than 12 Months of Unrealized Losses, Gross Unrealized Losses	-448	0
12 Months or More of Unrealized Losses, Estimated Fair Value	391	6,991
12 Months or More of Unrealized Losses, Gross Unrealized Losses	-82	-39
Total, Estimated Fair Value	5,096	6,991
Total, Gross Unrealized Losses	-530	-39
Gross unrealized gains	$2,120	$5,340

Recovered_Sheet6

Certain Financial Statement Information (Details 13) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Schedule of Warranty Reserve Activity	'	'	'	'
Beginning balance	$203	$447	$220	$454
Charged to costs of revenues	-11	85	-26	215
Charges incurred	-5	-162	-7	-299
Ending balance	$187	$370	$187	$370

Recovered_Sheet7

Certain Financial Statement Information (Details 14) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Schedule of Interest Income, Net	'	'	'	'
Interest income	$402	$568	$870	$1,230
Net realized gain on short-term investments	86	177	3,284	1,194
Interest income, net	$488	$745	$4,154	$2,424

Recovered_Sheet8

Certain Financial Statement Information (Details 15) (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Schedule of Reconciliation of Shares Used to Calculate Basic and Diluted Net (Loss) Income Per Share	'	'	'	'
Net loss (USD)	($32,383)	($21,557)	($21,526)	($44,947)
Shares used in net loss per share computation:	'	'	'	'
Weighted average common shares outstanding, basic	72,610	64,947	70,985	63,678
Net effect of dilutive common share equivalents	0	0	0	0
Weighted average common shares outstanding, diluted	72,610	64,947	70,985	63,678
Basic and diluted net loss per share (in dollars per share)	($0.45)	($0.33)	($0.30)	($0.71)

Recovered_Sheet9

Certain Financial Statement Information (Details Textual)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Certain Financial Statement Information (Textual) [Abstract]	'	'	'	'
Anti-dilutive securities that have been excluded from the net (loss) income, per share computation	6	10.7	6.5	10.7
Options and Restricted Stock Units [Member]	'	'	'	'
Certain Financial Statement Information (Textual) [Abstract]	'	'	'	'
Anti-dilutive securities that have been excluded from the net (loss) income, per share computation	4.3	10.2	5.2	10.3
Effect of dilutive securities that have been excluded from the net loss per share computation	1.7	0.5	1.3	0.4

Restructuring_Charges_Details_

Restructuring Charges (Details Textual) (USD $)	1 Months Ended	6 Months Ended					1 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2012	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Aug. 31, 2013	Sep. 30, 2013	Sep. 30, 2013
	December 2012 Restructuring Program [Member]	December 2012 Restructuring Program [Member]	December 2012 Restructuring Program [Member]	December 2012 Restructuring Program [Member]	December 2012 Restructuring Program [Member]	December 2012 Restructuring Program [Member]	August 2013 Restructuring Program [Member]	August 2013 Restructuring Program [Member]	August 2013 Restructuring Program [Member]	August 2013 Restructuring Program [Member]
	employee		Workforce Reduction [Member]	Workforce Reduction [Member]	Other Operational Expense [Member]	Other Operational Expense [Member]		employee	Workforce Reduction [Member]	Other Operational Expense [Member]
			Minimum [Member]	Maximum [Member]	Minimum [Member]	Maximum [Member]
Restructuring Charges (Textual) [Abstract]	'	'	'	'	'	'	'	'	'	'
Number of positions eliminated	70	'	'	'	'	'	'	20	'	'
Anticipated reduction in expenses	'	'	$8	$9	$4	$5	'	'	$3	$0.50
Restructuring costs incurred to date and expected to be incurred	'	1.8	'	'	'	'	'	'	'	'
Restructuring costs expected to be recognized	'	'	'	'	'	'	$1	'	'	'

Restructuring_Charges_Restruct

Restructuring Charges Restructuring Charges (Details 1) (USD $)	3 Months Ended			6 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Jun. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Restructuring Reserve [Roll Forward]	'	'	'	'	'
Liability, beginning balance	$307	$548	'	$548	'
Restructuring charges	999	93	0	1,092	0
Non-cash items	-272	'	'	'	'
Cash payments	-847	-334	'	'	'
Liability, ending balance	187	307	'	187	'
Workforce Reduction	'	'	'	'	'
Restructuring Reserve [Roll Forward]	'	'	'	'	'
Liability, beginning balance	307	548	'	548	'
Restructuring charges	727	93	'	'	'
Non-cash items	0	'	'	'	'
Cash payments	-847	-334	'	'	'
Liability, ending balance	187	307	'	187	'
Asset Impairment	'	'	'	'	'
Restructuring Reserve [Roll Forward]	'	'	'	'	'
Liability, beginning balance	0	0	'	0	'
Restructuring charges	272	0	'	'	'
Non-cash items	-272	'	'	'	'
Cash payments	0	0	'	'	'
Liability, ending balance	$0	$0	'	$0	'

Veloce_Details

Veloce (Details) (Veloce Technologies, Inc. [Member], USD $)	0 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended
In Millions, except Share data in Thousands, unless otherwise specified	Jun. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Jun. 30, 2013	Dec. 31, 2012	Jun. 20, 2012
Veloce Technologies, Inc. [Member]	'	'	'	'	'	'	'	'
Veloce (Textual) [Abstract]	'	'	'	'	'	'	'	'
Total consideration to be transferred	'	'	'	'	'	'	$178.50	$135
Research and development expenses incurred	65.1	30.4	2.3	39.7	4.6	166.3	'	'
Payment of aggregate consideration as cash	'	19.2	2.1	44.2	14.8	'	'	'
Aggregate shares issued	'	2,300	200	3,700	2,600	'	'	'
Stock issued for acquisition, value	'	19	1.1	29	14.8	'	'	'
Issuance of additional units	'	12,000	'	500	'	'	'	'
Issuance of additional units, amount	'	0.2	'	5.9	'	'	'	'
Unallocated units	'	800	'	800	'	'	'	'
Unallocated units, maximum potential value	'	$9.40	'	$9.40	'	'	'	'

Stockholders_Equity_Details_1

Stockholders' Equity (Details 1) (USD $)	6 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013
Schedule of Option Activity Under Stock Incentive Plans	'
Number of Shares, Outstanding at the beginning of the year	3,492
Number of Shares, Granted	40
Number of Shares, Exercised	-495
Number of Shares, Forfeited	-367
Number of Shares, Outstanding at the end of the period	2,670
Number of Shares, Vested at the end of the period	2,667
Schedule of Weighted Average Exercise Price Per Share Under Stock Incentive Plans	'
Weighted Average Exercise Price Per Share, Outstanding at the beginning of the year (USD per share)	$10.26
Weighted Average Exercise Price Per Share, Granted (USD per share)	$7.35
Weighted Average Exercise Price Per Share, Exercised (USD per share)	$8.97
Weighted Average Exercise Price Per Share, Forfeited (USD per share)	$10.15
Weighted Average Exercise Price Per Share, Outstanding at the end of the period (USD per share)	$10.47
Weighted Average Exercise Price Per Share, Vested at the end of the period (USD per share)	$10.47
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	2,512
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price	$10.56

Stockholders_Equity_Details_2

Stockholders' Equity (Details 2) (USD $)	6 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013
Weighted Average Remaining Contractual Life and Weighted Average Per Share Exercise Price of Options Outstanding and Options Exercisable	'
Weighted average remaining contractual term for options outstanding	'2 years 10 months 12 days
$ 1.68 - $ 7.60 [Member]	'
Weighted Average Remaining Contractual Life and Weighted Average Per Share Exercise Price of Options Outstanding and Options Exercisable	'
Range of Exercise Price, minimum (USD per share)	1.68
Range of Exercise Price, maximum (USD per share)	7.6
Number of Shares, Options Outstanding	570
Weighted average remaining contractual term for options outstanding	'3 years 6 months 13 days
Weighted Average Exercise Price, Options Outstanding (USD per share)	6.69
Number of Shares, Options Exercisable	472
Weighted Average Exercise Price, Options Exercisable (USD per share)	6.58
$ 7.61 - $ 7.67 [Member]	'
Weighted Average Remaining Contractual Life and Weighted Average Per Share Exercise Price of Options Outstanding and Options Exercisable	'
Range of Exercise Price, minimum (USD per share)	7.61
Range of Exercise Price, maximum (USD per share)	7.67
Number of Shares, Options Outstanding	650
Weighted average remaining contractual term for options outstanding	'2 years 10 months 4 days
Weighted Average Exercise Price, Options Outstanding (USD per share)	7.67
Number of Shares, Options Exercisable	650
Weighted Average Exercise Price, Options Exercisable (USD per share)	7.67
$ 7.68 - $ 11.86 [Member]	'
Weighted Average Remaining Contractual Life and Weighted Average Per Share Exercise Price of Options Outstanding and Options Exercisable	'
Range of Exercise Price, minimum (USD per share)	7.68
Range of Exercise Price, maximum (USD per share)	11.86
Number of Shares, Options Outstanding	469
Weighted average remaining contractual term for options outstanding	'3 years 7 months 6 days
Weighted Average Exercise Price, Options Outstanding (USD per share)	10.45
Number of Shares, Options Exercisable	431
Weighted Average Exercise Price, Options Exercisable (USD per share)	10.34
$ 11.87 - $ 14.20 [Member]	'
Weighted Average Remaining Contractual Life and Weighted Average Per Share Exercise Price of Options Outstanding and Options Exercisable	'
Range of Exercise Price, minimum (USD per share)	11.87
Range of Exercise Price, maximum (USD per share)	14.2
Number of Shares, Options Outstanding	599
Weighted average remaining contractual term for options outstanding	'2 years 7 months 17 days
Weighted Average Exercise Price, Options Outstanding (USD per share)	12.78
Number of Shares, Options Exercisable	577
Weighted Average Exercise Price, Options Exercisable (USD per share)	12.81
$ 14.21 - $ 23.32 [Member]	'
Weighted Average Remaining Contractual Life and Weighted Average Per Share Exercise Price of Options Outstanding and Options Exercisable	'
Range of Exercise Price, minimum (USD per share)	14.21
Range of Exercise Price, maximum (USD per share)	23.32
Number of Shares, Options Outstanding	382
Weighted average remaining contractual term for options outstanding	'1 year 7 months 9 days
Weighted Average Exercise Price, Options Outstanding (USD per share)	17.26
Number of Shares, Options Exercisable	382
Weighted Average Exercise Price, Options Exercisable (USD per share)	17.26
$ 1.68 - $ 23.32 [Member]	'
Weighted Average Remaining Contractual Life and Weighted Average Per Share Exercise Price of Options Outstanding and Options Exercisable	'
Range of Exercise Price, minimum (USD per share)	1.68
Range of Exercise Price, maximum (USD per share)	23.32
Number of Shares, Options Outstanding	2,670
Weighted average remaining contractual term for options outstanding	'2 years 10 months 24 days
Weighted Average Exercise Price, Options Outstanding (USD per share)	10.47
Number of Shares, Options Exercisable	2,512
Weighted Average Exercise Price, Options Exercisable (USD per share)	10.56

Stockholders_Equity_Details_3

Stockholders' Equity (Details 3) (Restricted Stock Units (RSUs) [Member])	6 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013
Restricted Stock Units (RSUs) [Member]	'
Schedule of Restricted Stock Unit Activity	'
Restricted Stock Units Outstanding Number of Shares, Outstanding at the beginning of the year	6,444
Restricted Stock Units Awarded	2,032
Restricted Stock Units Vested	-1,649
Restricted Stock Units Cancelled	-1,452
Restricted Stock Units Outstanding Number of Shares, Outstanding at the end of the period	5,375

Stockholders_Equity_Details_Te

Stockholders' Equity (Details Textual) (USD $)

6 Months Ended

12 Months Ended

6 Months Ended

1 Months Ended

6 Months Ended

1 Months Ended

6 Months Ended

6 Months Ended

6 Months Ended

6 Months Ended

12 Months Ended

1 Months Ended

1 Months Ended

6 Months Ended

1 Months Ended

6 Months Ended

1 Months Ended

6 Months Ended

104 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Mar. 31, 2013

Mar. 31, 2013

Sep. 30, 2013

31-May-13

Sep. 30, 2013

31-May-13

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Aug. 30, 2012

Sep. 30, 2012

Sep. 30, 2013

Aug. 30, 2010

Sep. 30, 2013

Apr. 30, 2011

Apr. 30, 2011

Sep. 30, 2013

Mar. 31, 2013

Mar. 31, 2013

Nov. 30, 2011

Nov. 30, 2011

Sep. 30, 2013

Jun. 30, 2012

31-May-12

Feb. 29, 2012

Nov. 30, 2011

Sep. 30, 2013

31-May-09

Apr. 30, 2011

Feb. 29, 2012

31-May-13

31-May-13

31-May-13

31-May-13

Feb. 29, 2012

Sep. 30, 2013

17-May-09

31-May-12

31-May-12

Oct. 31, 2008

Aug. 31, 2004

Sep. 30, 2013

Sep. 30, 2012

Mar. 31, 2013

Approved_Plan

RSU plan post May 2006 [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Employee Stock Purchase Plan [Member]

Employee Stock Purchase Plan [Member]

Employee Stock Purchase Plan [Member]

Employee Stock Purchase Plan [Member]

Employee Stock Purchase Plan [Member]

Employee Stock Purchase Plan [Member]

Employee Stock Purchase Plan [Member]

Stock Repurchase Program - Open Market [Member]

Company's 2011 Equity Incentive Plan [Member]

Company's 2011 Equity Incentive Plan [Member]

Restricted Stock Units [Member]

Restricted Stock Units [Member]

Restricted Stock Units [Member]

Restricted Stock Units [Member]

Restricted Stock Units [Member]

Common Stock Subject to Repurchase [Member]

Common Stock Subject to Repurchase [Member]

Performance-Based RSU [Member]

Performance-Based RSU [Member]

Performance-Based RSU [Member]

Performance-Based RSU [Member]

Performance-Based RSU [Member]

Performance-Based RSU [Member]

Performance-Based RSU [Member]

Performance-Based MSU [Member]

Performance-Based MSU [Member]

Performance-Based MSU [Member]

Performance-Based MSU [Member]

Officer [Member]

Veloce Technologies, Inc. [Member]

Veloce Technologies, Inc. [Member]

First Vesting Period [Member]

Second Vesting Period [Member]

August 2004 [Member]

August 2004 [Member]

August 2004 [Member]

August 2004 [Member]

August 2004 [Member]

FY2014 Short Term Plan [Member]

FY2014 Short Term Plan [Member]

2012 Employee Stock Purchase Plan [Member]

2012 Employee Stock Purchase Plan [Member]

2012 Employee Stock Purchase Plan [Member]

1998 Employee Stock Purchase Plan [Member]

1998 Employee Stock Purchase Plan [Member]

1998 Employee Stock Purchase Plan [Member]

Minimum [Member]

Maximum [Member]

RSU plan prior to May 2006 [Member]

RSU plan post May 2006 [Member]

Minimum [Member]

Maximum [Member]

milestone

milestone

May 2009 Plan [Member]

April 2011 Plan [Member]

November 2011 and February 2012 Plan [Member]

Minimum [Member]

Maximum [Member]

First Vesting Period [Member]

Second Vesting Period [Member]

Performance-Based RSU [Member]

quarter

November 2011 and February 2012 Plan [Member]

November 2011 and February 2012 Plan [Member]

Stockholders Equity [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock, shares authorized for issuance

2,000,000

'

2,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock, shares outstanding

0

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, shares authorized for issuance

375,000,000

'

375,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, shares issued

73,733,000

'

67,952,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, shares outstanding

73,733,000

'

67,952,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock reserved for issuance

'

'

'

'

'

'

'

'

'

'

'

'

'

4,800,000

6,300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares available for future issuance

'

'

'

'

'

'

'

'

'

800,000

'

1,800,000

'

'

'

'

4,200,000

10,900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of purchase price of common stock equal to fair market value

'

'

'

'

'

'

'

'

'

85.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, shares issued, employee stock purchase plan

'

'

'

'

'

'

'

'

0

300,000

0

'

400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock repurchase program, authorized amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$200,000,000

$15,900,000

'

'

Increase in the amount authorized for stock purchase program

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000,000

'

'

'

'

Stock repurchase program, shares repurchased

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

100,000

17,300,000

Stock repurchase program, weighted average price per share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$5.18

$10.04

Number of stockholder-approved plans

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of plans unapproved by stockholders

4

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Options expiration period, in years

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Vesting period, in years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'4 years

'4 years

'4 years

'1 year

'18 months

'

'

'1 year

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Vesting and exercisable rate of new hire grants, percentage

25.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in First Period of Employment

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Vesting and exercisable rate of new hire grants, grant date

'

'

'

'

'36 months

'

'48 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares outstanding

2,670,000

'

3,492,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted average remaining contractual term for options outstanding

'2 years 10 months 12 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate pretax intrinsic value of options exercised

1,300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Pre-tax intrinsic value of options outstanding

8,300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Pre-tax intrinsic value of options exercisable

7,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, closing price per share

$12.90

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$12.90

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Award vesting period, quarters

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

12

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Term of award

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'P12Y

'

'18-month

'

'P3Y

'P3Y

'P18M

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restricted stock units awarded

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,032,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

500,000

'

'

'

'

'

'

'

'

'

Number of milestones

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate intrinsic value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,700,000

'

'

'

'

'

'

'

'

'

Number of milestones completed

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Award performance period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'2 years

'3 years

'

'

'

'

'

'

'

'

'

'

Award vesting percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.00%

150.00%

'

'

'

'

'

'

'

'

'

'

'

'

Award pay out percentage

'

'

'

'

'

50.00%

'

150.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted average remaining contractual term for the restricted stock units outstanding, in years

'1 year 1 month 12 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate pre-tax intrinsic value of restricted stock units outstanding which includes performance based awards which are subject to milestone attainments

69,300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share Based Compensation Arrangement by Share Based Payment Award Equity Other than Options Aggregate Pre Tax Intrinsic Value Released

14,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of years of development work to be performed

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

Stock-based compensation expense related to the acceleration of Veloce warrants

$0

$1,289,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1,289,000

'

'

'

'

'

'

'

'

Award vesting percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

66.67%

33.33%

'

'

'

'

'

StockBased_Compensation_Detail

Stock-Based Compensation (Details) (USD $)	3 Months Ended		6 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Employee Stock Options [Member]	'	'	'	'
Schedule of Weighted-Average Assumptions Used to Estimate the Fair Value of Stock Options	'	'	'	'
Expected life	'	'	'4 years 4 months 24 days	'4 years 6 months
Risk-free interest rate	'	'	0.60%	0.70%
Volatility	'	'	49.00%	54.00%
Dividend yield	'	'	0.00%	0.00%
Weighted average fair value	'	'	$2.95	$2.47
Employee Stock Purchase Plans [Member]	'	'	'	'
Schedule of Weighted-Average Assumptions Used to Estimate the Fair Value of Stock Options	'	'	'	'
Expected life	'6 months	'6 months	'6 months	'6 months
Risk-free interest rate	0.10%	0.20%	0.10%	0.20%
Volatility	57.00%	50.00%	57.00%	50.00%
Dividend yield	0.00%	0.00%	0.00%	0.00%
Weighted average fair value	$3.67	$0	$3.67	$1.50

StockBased_Compensation_Detail1

Stock-Based Compensation (Details 1) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Summary of Stock-Based Compensation Expense of Stock Options and Restricted Stock Units	'	'	'	'
Stock options (including employee stock purchase program)	$3,836	$7,632	$7,562	$15,240
Stock-based compensation expensed from inventory	2	-2	14	-83
Total stock-based compensation expense	3,834	7,634	7,548	15,323
Stock Options [Member]	'	'	'	'
Summary of Stock-Based Compensation Expense of Stock Options and Restricted Stock Units	'	'	'	'
Stock options (including employee stock purchase program)	737	601	1,339	2,089
Restricted Stock Units [Member]	'	'	'	'
Summary of Stock-Based Compensation Expense of Stock Options and Restricted Stock Units	'	'	'	'
Stock options (including employee stock purchase program)	$3,099	$7,031	$6,223	$13,151

StockBased_Compensation_Detail2

Stock-Based Compensation (Details 2) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Summary of Stock-Based Compensation Expense	'	'	'	'
Stock based compensation	$3,836	$7,632	$7,562	$15,240
Stock-based compensation expensed from inventory	-2	2	-14	83
Total stock-based compensation expense	3,834	7,634	7,548	15,323
Cost of Revenues [Member]	'	'	'	'
Summary of Stock-Based Compensation Expense	'	'	'	'
Stock based compensation	127	175	235	355
Research and Development [Member]	'	'	'	'
Summary of Stock-Based Compensation Expense	'	'	'	'
Stock based compensation	1,524	3,714	3,322	7,919
Selling, General and Administrative [Member]	'	'	'	'
Summary of Stock-Based Compensation Expense	'	'	'	'
Stock based compensation	$2,185	$3,743	$4,005	$6,966

StockBased_Compensation_Detail3

Stock-Based Compensation (Details Textual) (USD $)	3 Months Ended			6 Months Ended		12 Months Ended
	Sep. 30, 2013	Jun. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Mar. 31, 2013
Stock Based Compensation (Textual) [Abstract]	'	'	'	'	'	'
Weighted average grant-date fair value per share of the restricted stock units awarded	$11.97	'	$5.75	$8	$5.52	'
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Forfeiture Rate	'	6.70%	'	'	'	6.60%
Unearned stock-based compensation	$17,900,000	'	'	$17,900,000	'	'
Weighted-average period over which the unearned stock-based compensation is expected to be recognized, years	'	'	'	'1 year 8 months 18 days	'	'
Stock-based compensation expense excluding acceleration of Veloce warrants	3,834,000	'	7,634,000	7,548,000	15,323,000	'
Stock-based compensation expense related to the acceleration of Veloce warrants	'	'	'	0	1,289,000	'
Veloce Technologies Inc [Member]	'	'	'	'	'	'
Stock Based Compensation (Textual) [Abstract]	'	'	'	'	'	'
Stock-based compensation expense related to the acceleration of Veloce warrants	'	'	'	$1,289,000	'	'

Contingencies_Details

Contingencies (Details)	1 Months Ended		6 Months Ended
	Jan. 31, 2012	Jan. 31, 2009	Sep. 30, 2013
		Amendments	Company
Contingencies (Textual) [Abstract]	'	'	'
Companies named as Potentially Responsible Parties (more than)	'	'	100
Amendments approved to consent decree	'	2	'
Percent of contribution to the total waste	0.50%	'	'

Sale_of_TPack_AS_Details

Sale of TPack A/S (Details) (USD $)	3 Months Ended		6 Months Ended		0 Months Ended	6 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Apr. 22, 2013	Sep. 30, 2013
					TPack [Member]	TPack [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'	'	'	'	'	'
Adjusted sale price of entity	'	'	'	'	$33,500	'
Agreed upon price for sale of entity	'	'	'	'	34,000	'
Working capital adjustment to sale price	'	'	'	'	500	'
Disposal Group, Not Discontinued Operation, Disposal Disclosures [Abstract]	'	'	'	'	'	'
Total proceeds, net of working capital adjustment	'	'	'	'	30,175	'
Net assets and liabilities	'	'	'	'	-184	'
Goodwill write off	'	'	'	'	-1,757	'
Intangibles write off	'	'	'	'	-11,404	11,400
Holdback amount	'	'	'	'	3,353	'
Legal fees and other costs	'	'	'	'	-484	'
Gain on sale of TPack	0	0	19,699	0	19,699	'
Cash, cash equivalents and short term investments	'	'	'	'	$700	'